http://www.visiongain.com/ this is report feed for pharma dipesh_hirani@byteart.com (Dipesh Hirani) http://cyber.law.harvard.edu/rss/rss.html http://www.visiongain.com/graphics/logo.gifhttp://www.visiongain.com/ 60 http://www.visiongain.com/Report/1048/World-Biological-Drugs-Market-2013-2023 http://www.visiongain.com/Report/1048/World-Biological-Drugs-Market-2013-2023 pharma Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects. In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected products. info@visiongain.com (visiongain) Mon, 13 May 2013 00:00:00 GMT http://www.visiongain.com/Report/1042/Drug-Delivery-Technologies-Commercial-Prospects-2013-2023 http://www.visiongain.com/Report/1042/Drug-Delivery-Technologies-Commercial-Prospects-2013-2023 pharma What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2023 at world market, submarket, application and national level. info@visiongain.com (visiongain) Fri, 03 May 2013 00:00:00 GMT http://www.visiongain.com/Report/1039/Biosimilars-And-Follow-On-Biologics-World-Market-2013-2023 http://www.visiongain.com/Report/1039/Biosimilars-And-Follow-On-Biologics-World-Market-2013-2023 pharma Biosimilar drugs - discover trends and areas with highest revenue potential. Do you want to find the sales potential of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities and discussions of prospects. In that work you see forecasted sales to 2023 at overall world market, submarket, molecule and national level. You also assess emerging trends, technologies and expected products. info@visiongain.com (visiongain) Tue, 30 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1037/Point-of-Care-Coagulation-Testing-World-Market-2013-2023 http://www.visiongain.com/Report/1037/Point-of-Care-Coagulation-Testing-World-Market-2013-2023 pharma In 2011, the global point of care diagnostics market was worth $13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The preference for at home testing and its convenience will continue to drive the point of care diagnostics market. info@visiongain.com (visiongain) Fri, 26 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1033/Diabetes-Treatments-World-Drug-Market-2013-2023 http://www.visiongain.com/Report/1033/Diabetes-Treatments-World-Drug-Market-2013-2023 pharma Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world antidiabetic medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments. info@visiongain.com (visiongain) Wed, 24 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1029/Rheumatoid-Arthritis-(RA)-World-Drug-Market-2013-2023 http://www.visiongain.com/Report/1029/Rheumatoid-Arthritis-(RA)-World-Drug-Market-2013-2023 pharma Where's the arthritic treatment market heading? Visiongain's updated report gives you forecasted revenues to 2023 for drugs treating human rheumatoid arthritis (RA). There you find R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments. info@visiongain.com (visiongain) Fri, 19 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1030/Needle-Free-Delivery-Technology-And-Market-2013-2023 http://www.visiongain.com/Report/1030/Needle-Free-Delivery-Technology-And-Market-2013-2023 pharma What does the future hold for the needle-free delivery market? Visiongain's report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for the overall needle-free injection technology market. There is urgent need for needle-free delivery methods, driven by needle/syringe safety concerns and their lack of suitability for mass immunisation programmes. Our study lets you assess sales data for the global needle-free delivery market, its submarkets and leading national markets. info@visiongain.com (visiongain) Fri, 19 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1021/Infusion-Pumps-Technology-and-Market-2013-2023 http://www.visiongain.com/Report/1021/Infusion-Pumps-Technology-and-Market-2013-2023 pharma What does the future hold for the infusion pumps market? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for infusion pumps. Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses. info@visiongain.com (visiongain) Wed, 10 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1018/Chinese-Pharmaceutical-Market-2013-2023 http://www.visiongain.com/Report/1018/Chinese-Pharmaceutical-Market-2013-2023 pharma What's the outlook for the Chinese pharma market? Can it sustain high growth? Visiongain's updated report gives you forecasted revenues there to 2023. Our study lets you assess sales data and detailed predictions. There, you investigate activities of domestic and international companies and assess their environment. That analysis shows you Chinese pharma's most promising and lucrative areas. info@visiongain.com (visiongain) Tue, 09 Apr 2013 00:00:00 GMT http://www.visiongain.com/Report/1012/Ophthalmic-Drugs-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/1012/Ophthalmic-Drugs-World-Market-Prospects-2013-2023 pharma What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs. Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses. info@visiongain.com (visiongain) Wed, 27 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/1013/Pharma-Leader-Series-Top-Pre-Filled-Injection-Device-Manufacturers-2013-2023 http://www.visiongain.com/Report/1013/Pharma-Leader-Series-Top-Pre-Filled-Injection-Device-Manufacturers-2013-2023 pharma How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices. Our updated study lets you assess leading companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2023. There you see financial results, interviews, trends, opportunities and revenue predictions. info@visiongain.com (visiongain) Mon, 25 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/1009/Antibacterial-Drugs-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/1009/Antibacterial-Drugs-World-Market-Prospects-2013-2023 pharma Where's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world antibacterial drugs market, therapeutic submarkets, important products and national markets. info@visiongain.com (visiongain) Thu, 21 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/1006/Biobanking-For-Medicine-Technology-And-Market-2013-2023 http://www.visiongain.com/Report/1006/Biobanking-For-Medicine-Technology-And-Market-2013-2023 pharma See what the future holds for biobanking in human medicine. Visiongain's updated report gives you its revenue predictions to 2023. Our study shows you the potential of technologies, products and services for that archiving of medical biosamples. In that work you see forecasted sales at overall world market, submarket and national level. info@visiongain.com (visiongain) Mon, 18 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/1004/Immunochemistry-Reagents-Analysers-And-Test-Kits-World-Market-2013-2023 http://www.visiongain.com/Report/1004/Immunochemistry-Reagents-Analysers-And-Test-Kits-World-Market-2013-2023 pharma What does the future hold for the immunochemistry market? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for immunochemistry reagents, analysers and test kits. Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses. info@visiongain.com (visiongain) Fri, 15 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/998/Medical-Device-Leader-Series-Top-In-Vitro-Diagnostics-Companies-2013-2023 http://www.visiongain.com/Report/998/Medical-Device-Leader-Series-Top-In-Vitro-Diagnostics-Companies-2013-2023 pharma What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain's new report shows you their prospects to 2023. There you see financial results, trends, opportunities and revenue predictions. To help you assess the future of that industry and market, our study analyses 18 leading IVD developers and manufacturers. info@visiongain.com (visiongain) Mon, 11 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/996/Gastrointestinal-Devices-World-Market-2013-2023 http://www.visiongain.com/Report/996/Gastrointestinal-Devices-World-Market-2013-2023 pharma What does the future hold for treating gastrointestinal disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for gastrointestinal devices. Developments worldwide will influence the market from 2013, especially the expansion of healthcare in emerging countries. There exist many opportunities for medical device companies developing technologies for treating gastrointestinal disorders. info@visiongain.com (visiongain) Wed, 06 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/993/Dermatological-Drugs-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/993/Dermatological-Drugs-World-Market-Prospects-2013-2023 pharma What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains R&D trends, outlooks and opportunities. Our study lets you assess sales data for the world market, therapeutic submarkets, products and national markets. info@visiongain.com (visiongain) Tue, 05 Mar 2013 00:00:00 GMT http://www.visiongain.com/Report/988/Cell-Based-Assays-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/988/Cell-Based-Assays-World-Market-Prospects-2013-2023 pharma Find what the future holds for cell assay technologies. Visiongain's updated report gives you revenue predictions to 2023. There you discover sales data, R&D trends, opportunities and prospects. You find the potential of those biotechnologies. See forecasted sales at overall world market, submarket and national level. Also you assess emerging trends and predicted events. Many opportunities remain - you discover the areas to prosper. info@visiongain.com (visiongain) Mon, 25 Feb 2013 00:00:00 GMT http://www.visiongain.com/Report/982/Antithrombotic-Drugs-World-Market-2013-2023 http://www.visiongain.com/Report/982/Antithrombotic-Drugs-World-Market-2013-2023 pharma What does the future hold for treating conditions associated with thrombosis? Visiongain's updated report gives you forecasted revenues to 2023, explaining R&D trends, outlooks and opportunities. Our study lets you assess sales data for the world market, submarkets, products and national markets. There you find that industry's most promising and lucrative segments. info@visiongain.com (visiongain) Thu, 14 Feb 2013 00:00:00 GMT http://www.visiongain.com/Report/978/Next-Generation-Antibody-Therapeutics-Market-2013-2023 http://www.visiongain.com/Report/978/Next-Generation-Antibody-Therapeutics-Market-2013-2023 pharma Where are therapeutic antibodies heading? Visiongain's updated report gives you revenue predictions to 2023. There you see sales data, R&D trends, outlooks and opportunities. You find the potential of monoclonal antibodies (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected products. Many opportunities remain - you discover the areas to prosper. info@visiongain.com (visiongain) Tue, 05 Feb 2013 00:00:00 GMT http://www.visiongain.com/Report/973/Pharma-Clinical-Trial-Services-World-Market-2013-2023 http://www.visiongain.com/Report/973/Pharma-Clinical-Trial-Services-World-Market-2013-2023 pharma What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects. Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses. info@visiongain.com (visiongain) Fri, 25 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/970/Medical-Device-Contract-Manufacturing-World-Market-Outlook-2013-2023 http://www.visiongain.com/Report/970/Medical-Device-Contract-Manufacturing-World-Market-Outlook-2013-2023 pharma The medical device contract manufacturing market will witness significant growth during 2013-2023, driven by an expanding medical devices market. According to visiongain estimates, the global medical devices market was worth $266.0bn in 2011. In the past, the medical device industry maintained a low level of outsourcing due to concerns over quality, delays and regulatory compliance. In recent years however, outsourcing has become more attractive, driven by the Original Equipment Manufacturers (OEMs) need to reduce costs and to accelerate the time to market. info@visiongain.com (visiongain) Wed, 23 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/966/Vaccine-Manufacturing-Technology-and-Services-World-Market-2013-2023 http://www.visiongain.com/Report/966/Vaccine-Manufacturing-Technology-and-Services-World-Market-2013-2023 pharma What's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies. Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses. There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues. info@visiongain.com (visiongain) Wed, 16 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/961/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/961/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2013-2023 pharma What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects. That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading. info@visiongain.com (visiongain) Wed, 09 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/962/Medical-Device-Leader-Series-Top-Companion-Diagnostic-Companies-2013-2023 http://www.visiongain.com/Report/962/Medical-Device-Leader-Series-Top-Companion-Diagnostic-Companies-2013-2023 pharma A myriad of pharmaceutical and diagnostic companies are now entering the highly attractive market of companion diagnostics, many of them entering into collaborations for developing a combination product. Apart from the well-known pharmaceutical and diagnostic companies, some small, niche-companies are also focusing on companion diagnostic development. At present, competition is largely dependent on the ability to collaborate with biotechnology and pharmaceutical companies to develop and commercialise these tests for their therapeutic drugs and drug candidates. info@visiongain.com (visiongain) Wed, 09 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/956/Neuromodulation-Devices-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/956/Neuromodulation-Devices-World-Market-Prospects-2013-2023 pharma Neuromodulation is one of the fastest growing sectors of the medical device market. Neuromodulation is a rapidly evolving medical technique that provides symptomatic relief through the alteration, or modulation, of nerve system function. It works by either stimulating nerves to produce a natural biological response or by applying small doses of pharmaceutical agents directly to the site of action. info@visiongain.com (visiongain) Wed, 02 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/957/Parkinson's-Disease-World-Drug-Market-2013-2023 http://www.visiongain.com/Report/957/Parkinson's-Disease-World-Drug-Market-2013-2023 pharma Where are treatments for Parkinson's disease heading - technological and commercial outlooks? Visiongain's updated report gives you forecasted revenues to 2023 and shows you R&D trends, opportunities and industry prospects. Emerging technologies hold promise. Our new study investigates developments, also letting you assess projected sales data at overall world market, submarket and national level. There you investigate the most promising areas in that industry and market segment for neurodegenerative disorders. info@visiongain.com (visiongain) Wed, 02 Jan 2013 00:00:00 GMT http://www.visiongain.com/Report/948/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2013-2023 http://www.visiongain.com/Report/948/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2013-2023 pharma What does the future hold for small targeted agents to treat cancers? Visiongain's updated report gives you revenue predictions to 2023. There you find sales data, R&D trends, opportunities and commercial prospects. You see the potential of those molecularly-targeted technologies and products. Our new analysis lets you assess forecasted sales at overall world market, product and national level. Discover how and why revenues can increase. info@visiongain.com (visiongain) Mon, 10 Dec 2012 00:00:00 GMT http://www.visiongain.com/Report/945/Drug-Discovery-Outsourcing-World-Market-2013-2023 http://www.visiongain.com/Report/945/Drug-Discovery-Outsourcing-World-Market-2013-2023 pharma See what the future holds for outsourcing early-stage drug development. There is rising demand for those services. Visiongain's updated report gives you revenue predictions to 2023, showing you data, trends, opportunities and commercial prospects. info@visiongain.com (visiongain) Fri, 30 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/940/Advanced-Wound-Care-World-Market-Prospects-2013-2023 http://www.visiongain.com/Report/940/Advanced-Wound-Care-World-Market-Prospects-2013-2023 pharma The demand for advanced wound care products is expected to rise over the next 10 years, driven by an increase in chronic wounds. This can be attributed to an aging population and an increase in lifestyle related disorders such as diabetes and obesity. Visiongain predicts the total advanced wound care market to be worth $16.3bn in 2023. info@visiongain.com (visiongain) Wed, 28 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/932/Generic-Drugs-World-Market-2013-2023 http://www.visiongain.com/Report/932/Generic-Drugs-World-Market-2013-2023 pharma Where's the generic drugs market heading? Visiongain's updated report gives you revenue predictions to 2023. That new study lets you assess forecasted sales at overall world market and national level. You discover the potential of the generics market, seeing how, why and where it can grow. As pharma patents expire, much opportunity remains. info@visiongain.com (visiongain) Tue, 13 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/933/Indian-Medical-Device-Market-Outlook-2013-2023 http://www.visiongain.com/Report/933/Indian-Medical-Device-Market-Outlook-2013-2023 pharma India is one of the most lucrative markets for medical devices globally. With the market relying largely on imports, the country provides significant opportunities for multinational medical device manufacturers. The domestic manufacturers are mostly engaged in low-value products like syringes, needles, catheters, blood collection tubes, medical electronics, medical equipment and implants. info@visiongain.com (visiongain) Tue, 13 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/927/Self-Monitoring-Blood-Glucose-Devices-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/927/Self-Monitoring-Blood-Glucose-Devices-World-Market-Outlook-2012-2022 pharma Medical devices are playing an increasingly important role in diabetes. Products such as blood glucose monitors and insulin pumps have now become the cornerstone for management of blood glucose levels. Self monitoring blood glucose (SMBG) monitors are gaining popularity with increasing number of patients getting more aware of the need to better manage their diabetes and going for regular home monitoring of their blood glucose levels. The ease of use of SMBG devices has been a driving factor for their adoption. info@visiongain.com (visiongain) Tue, 06 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/928/World-Pharmaceutical-Contract-Sales-Market-2013-2023 http://www.visiongain.com/Report/928/World-Pharmaceutical-Contract-Sales-Market-2013-2023 pharma Where are pharma contract sales organisations (CSOs) heading? Visiongain's updated report gives you forecasted revenues to 2023 for that market and shows you trends, opportunities and industry prospects. For sales outsourcing our study lets you assess projected sales data at overall world market, submarket and national level. info@visiongain.com (visiongain) Tue, 06 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/925/Urology-Devices-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/925/Urology-Devices-World-Market-Outlook-2012-2022 pharma The urology device market is one of the largest markets of the medical devices industry. The market is currently comprised of innovative urology devices for the treatment of a wide range of disorders that include urinary incontinence, prostate cancer, benign prostatic hyperplasia (BPH) and kidney stones. It is an attractive and highly profitable market and therefore an intensely competitive one. This is clearly demonstrated by the considerable number of recent mergers and acquisitions within this sector well as the myriad of devices and technologies that are expected to be launched in the coming years. info@visiongain.com (visiongain) Fri, 02 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/924/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-(DR)-World-Drug-Market-2013-2023 http://www.visiongain.com/Report/924/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-(DR)-World-Drug-Market-2013-2023 pharma Where are treatments for macular degeneration (AMD) and diabetic retinopathy (DR) heading? Visiongain's updated report gives you revenue predictions to 2023 for those eye disorders. This new study lets you assess forecasted sales at overall world market, submarket, product and national level. You discover the potential of that ophthalmic drug market, seeing how and why it can grow. info@visiongain.com (visiongain) Thu, 01 Nov 2012 00:00:00 GMT http://www.visiongain.com/Report/919/Pharmaceutical-Anti-counterfeiting-Technologies-Market-Analysis-2012-2022 http://www.visiongain.com/Report/919/Pharmaceutical-Anti-counterfeiting-Technologies-Market-Analysis-2012-2022 pharma Where is the pharma anti-counterfeiting industry heading? Visiongain's updated report gives you forecasted revenues to 2022 and shows you trends, opportunities and industry prospects. Our study investigates technologies to tackle drug counterfeiters. It lets you assess projected sales data at overall world market, submarket and national level. There you investigate the most lucrative areas in that industry and market, seeing future outlooks. info@visiongain.com (visiongain) Fri, 26 Oct 2012 00:00:00 GMT http://www.visiongain.com/Report/911/Pharma-Leader-Series-Top-20-Ophthalmic-Drug-Manufacturers-2012-2022 http://www.visiongain.com/Report/911/Pharma-Leader-Series-Top-20-Ophthalmic-Drug-Manufacturers-2012-2022 pharma What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's new report shows you their prospects to 2022. You find financial data, trends, opportunities and revenue predictions. We analyse 29 leading companies for eye medicines, to help you see the future of that industry and market. Discover how sales of ocular drugs can increase. info@visiongain.com (visiongain) Tue, 16 Oct 2012 00:00:00 GMT http://www.visiongain.com/Report/910/Large-Joint-Reconstruction-Global-Market-Prospects-2012-2022 http://www.visiongain.com/Report/910/Large-Joint-Reconstruction-Global-Market-Prospects-2012-2022 pharma The large joint reconstruction market is the principal segment of the orthopaedic devices market and was valued to be worth $12.8bn in 2011. Hip and knee implants constitute the major sub segments of this market. However, the market remained under pressure due to slow recovery following the 2008 economic recession. Decrease in procedure volumes, high unemployment rates and increase in pricing pressures have significantly affected the hip and knee implants market. Most patients preferred living with pain and discomfort than opting for costly replacement procedures, slowing down the growth of the industry. info@visiongain.com (visiongain) Fri, 12 Oct 2012 00:00:00 GMT http://www.visiongain.com/Report/906/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2012-2022 http://www.visiongain.com/Report/906/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2012-2022 pharma What does the future hold for top companies in the biosimilars industry? Visiongain's new report shows you their prospects to 2022. You find financial data, trends, opportunities and revenue potentials. We analyse 25 leading developers and producers of biosimilars (follow-on biologics). Our analyses help you see the future of that industry and market. info@visiongain.com (visiongain) Mon, 01 Oct 2012 00:00:00 GMT http://www.visiongain.com/Report/905/Therapeutic-Respiratory-Devices-Global-Market-Outlook-2012-2022 http://www.visiongain.com/Report/905/Therapeutic-Respiratory-Devices-Global-Market-Outlook-2012-2022 pharma The medical device industry has witnessed explosive growth in recent years. According to visiongain estimates, the global market was worth $266.0bn in 2011. Much of this growth is linked to the rising prevalence of a number of diseases worldwide; most notably in cardiac and neurological systems. After the negative effects the recession had on healthcare budgets in 2009, the medical device industry began to recover owing to patient demographics, physician adoption and patient demand. The medical device industry is one of the largest and fastest growing areas of the medical and pharmaceutical industries. info@visiongain.com (visiongain) Fri, 28 Sep 2012 00:00:00 GMT http://www.visiongain.com/Report/895/World-Multiple-Myeloma-Drug-Treatment-Market-2012-2022 http://www.visiongain.com/Report/895/World-Multiple-Myeloma-Drug-Treatment-Market-2012-2022 pharma See what the future holds for products to treat multiple myeloma. Visiongain's updated report gives you revenue predictions to 2022. There you find data, trends, opportunities and commercial prospects. Our study lets you assess forecasted sales at overall world market, product and national level. info@visiongain.com (visiongain) Mon, 17 Sep 2012 00:00:00 GMT http://www.visiongain.com/Report/893/Medical-Device-Leader-Series-Top-Needle-Free-Injection-Device-Manufacturers-2012-2022 http://www.visiongain.com/Report/893/Medical-Device-Leader-Series-Top-Needle-Free-Injection-Device-Manufacturers-2012-2022 pharma Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022 analyses the top 14 companies involved in the needle free injection (NFI) device market. This report also provides sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis of the overall NFI device market. There are over 38 tables and figures included. The result is comprehensive profiles on the leading companies operating in the NFI device market with detailed analyses and informed opinion to benefit your work. info@visiongain.com (visiongain) Fri, 14 Sep 2012 00:00:00 GMT http://www.visiongain.com/Report/889/Pharma-Leader-Series-Top-20-Biological-Drug-Manufacturers-2012-2022 http://www.visiongain.com/Report/889/Pharma-Leader-Series-Top-20-Biological-Drug-Manufacturers-2012-2022 pharma How are companies in the biological medicines (biologics) industry performing? Visiongain's new report shows you organisations' prospects to 2022. There you find financial data, trends, opportunities and commercial potentials. We assess 20 leading developers and producers of biological drugs and vaccines - our analyses help you see the future of the biopharma industry and market. info@visiongain.com (visiongain) Mon, 10 Sep 2012 00:00:00 GMT http://www.visiongain.com/Report/886/Translational-Regenerative-Medicine-Market-Prospects-2012-2022 http://www.visiongain.com/Report/886/Translational-Regenerative-Medicine-Market-Prospects-2012-2022 pharma See what the future holds for translational regenerative medicine. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product and regional level to 2022. How will four leading products - Apligraf, Dermagraft, DeNovo NT and Osteocel Plus - perform to 2022? You find business research and analysis with individual revenue forecasts and discussions. info@visiongain.com (visiongain) Fri, 31 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/880/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/880/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2012-2022 pharma How does the future look for pharmaceutical contract manufacturing? Visiongain's report gives you sales predictions to 2022. You find data, trends, opportunities and commercial prospects. In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, including discussions of regulatory and commercial developments. info@visiongain.com (visiongain) Mon, 20 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/879/Chinese-Medical-Device-Market-Outlook-2012-2022 http://www.visiongain.com/Report/879/Chinese-Medical-Device-Market-Outlook-2012-2022 pharma China is integral to the overall growth of the global medical devices market. This is because the market in China is primarily import-driven, and with the country's GDP growing at a rate of 10% per annum, there will be increased demand for imported medical equipment, especially from westernised countries that dominate the global market. info@visiongain.com (visiongain) Tue, 14 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/877/Lyophilisation-for-Pharmaceuticals-Products-and-Services-Market-2012-2022 http://www.visiongain.com/Report/877/Lyophilisation-for-Pharmaceuticals-Products-and-Services-Market-2012-2022 pharma What are the commercial prospects for pharmaceutical freeze drying? Visiongain's report gives you revenue predictions to 2022 for equipment, services and applications. Our updated study lets you assess forecasted sales at overall world market, submarket, application and national level. info@visiongain.com (visiongain) Mon, 13 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012-2022 http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012-2022 pharma See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2022. You find data, trends, opportunities and commercial prospects. That new study lets you assess forecasted sales at overall world market, submarket, product and national level. info@visiongain.com (visiongain) Wed, 08 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/865/Spinal-Implants-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/865/Spinal-Implants-World-Market-Outlook-2012-2022 pharma The spinal implants market is one of the largest sectors of the orthopaedics industry. It is an attractive and highly profitable market and therefore an intensely competitive one. This is clearly demonstrated by the sheer number of devices that are expected to be launched by the end of 2012 and the vast number of devices that are reported to be currently in different stages of development. info@visiongain.com (visiongain) Tue, 07 Aug 2012 00:00:00 GMT http://www.visiongain.com/Report/859/World-Vaccines-Market-2012-2022 http://www.visiongain.com/Report/859/World-Vaccines-Market-2012-2022 pharma Where is the vaccines sector heading? Visiongain's report shows you forecasted revenues to 2022. You see data, trends, opportunities and industry prospects. Our new study investigates vaccines for human beings, letting you assess projected sales at overall world market, submarket, product and national level. Many segments hold growth potential. info@visiongain.com (visiongain) Wed, 25 Jul 2012 00:00:00 GMT http://www.visiongain.com/Report/852/Biomarkers-Technological-and-Commercial-Outlook-2012-2022 http://www.visiongain.com/Report/852/Biomarkers-Technological-and-Commercial-Outlook-2012-2022 pharma What are the prospects for biomarker research, products and services? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, outlooks and opportunities. Our new study analyses the commercial potential for biomarker products and services. You find projected revenues to 2022 at world market, submarket, leading scientific discipline, leading indication and national market level. info@visiongain.com (visiongain) Mon, 16 Jul 2012 00:00:00 GMT http://www.visiongain.com/Report/849/Medical-Devices-Industry-and-Market-Prospects-2012-2022 http://www.visiongain.com/Report/849/Medical-Devices-Industry-and-Market-Prospects-2012-2022 pharma In 2011, the medical device market worldwide was worth $266.0bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The rise in neurological disorders will drive both the diagnostics market and the neurological device market. Changes in wealth and lifestyle globally, particularly in the emerging markets, will lead to a rise in obesity and coronary diseases. info@visiongain.com (visiongain) Wed, 11 Jul 2012 00:00:00 GMT http://www.visiongain.com/Report/847/Pre-Filled-Syringes-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/847/Pre-Filled-Syringes-World-Market-Prospects-2012-2022 pharma What are the commercial prospects for pre-filled syringes and related technologies? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, opportunities and prospects. Our new study analyses those parenteral devices and their therapeutic applications. You find projected sales to 2022 at overall world market, submarket, injected drug and national level. info@visiongain.com (visiongain) Mon, 02 Jul 2012 00:00:00 GMT http://www.visiongain.com/Report/845/In-Vitro-Diagnostics-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/845/In-Vitro-Diagnostics-World-Market-Outlook-2012-2022 pharma How will the in vitro diagnostics (IVD) market develop this decade? Our report shows you potential revenues to 2022, discussing opportunities and prospects. Our new study shows you potential revenues to 2022 for in vitro diagnostics at total world, submarket and national levels. What technologies and applications will expand that market? What effects will changes have? info@visiongain.com (visiongain) Wed, 27 Jun 2012 00:00:00 GMT http://www.visiongain.com/Report/841/Pharma-Leader-Series-Top-20-Antibacterial-Drug-Manufacturers-2012-2022 http://www.visiongain.com/Report/841/Pharma-Leader-Series-Top-20-Antibacterial-Drug-Manufacturers-2012-2022 pharma How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers. See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022. info@visiongain.com (visiongain) Thu, 21 Jun 2012 00:00:00 GMT http://www.visiongain.com/Report/839/Pharma-Wholesale-and-Distribution-Market-World-Outlook-2012-2022 http://www.visiongain.com/Report/839/Pharma-Wholesale-and-Distribution-Market-World-Outlook-2012-2022 pharma Where is the pharmaceutical wholesale and distribution (W&D) industry heading? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. This new study investigates the W&D industry and its market environment. It lets you discover projected revenues at overall world market, main submarket, company and national level to 2022. info@visiongain.com (visiongain) Tue, 19 Jun 2012 00:00:00 GMT http://www.visiongain.com/Report/833/World-OTC-Pharmaceutical-Market-2012-2022 http://www.visiongain.com/Report/833/World-OTC-Pharmaceutical-Market-2012-2022 pharma What does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there. This new study investigates OTC (over-the-counter) pharmaceuticals: medicines sold without prescriptions. It lets you assess projected sales at world market, therapeutic submarket, product and national level to 2022. info@visiongain.com (visiongain) Wed, 06 Jun 2012 00:00:00 GMT http://www.visiongain.com/Report/826/Stem-Cell-Technologies-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/826/Stem-Cell-Technologies-World-Market-Outlook-2012-2022 pharma What does the future hold for stem cells in medicine? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there. This new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too - outlooks, challenges, patenting and regulations. info@visiongain.com (visiongain) Wed, 23 May 2012 00:00:00 GMT http://www.visiongain.com/Report/819/Neuroprotective-Products-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/819/Neuroprotective-Products-World-Market-Prospects-2012-2022 pharma What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks. Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022. In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022? info@visiongain.com (visiongain) Thu, 10 May 2012 00:00:00 GMT http://www.visiongain.com/Report/815/Hepatitis-Treatments-and-Vaccines-World-Market-2012-2022 http://www.visiongain.com/Report/815/Hepatitis-Treatments-and-Vaccines-World-Market-2012-2022 pharma Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022. info@visiongain.com (visiongain) Wed, 02 May 2012 00:00:00 GMT http://www.visiongain.com/Report/813/Nuclear-Medicine-Imaging-Devices-Global-Market-Prospects-2012-2022 http://www.visiongain.com/Report/813/Nuclear-Medicine-Imaging-Devices-Global-Market-Prospects-2012-2022 pharma Our latest pharma report - Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022 - offers a comprehensive view of the global nuclear medicine imaging systems market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses, revealing areas that will experience growth and present new business opportunities. info@visiongain.com (visiongain) Tue, 01 May 2012 00:00:00 GMT http://www.visiongain.com/Report/807/Ultrasound-Systems-Global-Market-Outlook-2012-2022 http://www.visiongain.com/Report/807/Ultrasound-Systems-Global-Market-Outlook-2012-2022 pharma Our latest pharma report - Ultrasound Systems: Global Market Outlook 2012-2022 - offers a comprehensive view of the global ultrasound scanners market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses, revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the ultrasound systems market in 2011 to be worth $4.2bn. Growth in this market will be driven by new technology and varied uses of the technology. info@visiongain.com (visiongain) Fri, 20 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/808/World-Market-for-Orthopaedic-Extremity-Devices-2012-2022 http://www.visiongain.com/Report/808/World-Market-for-Orthopaedic-Extremity-Devices-2012-2022 pharma Our new report World Market for Orthopaedic Extremity Devices 2012-2022 covers the trends in the extremity implants market, a promising segment of the orthopaedic sector. Extremity reconstruction is one of the fastest growing segments of the artificial joints market of the orthopaedic devices industry. The extremity devices market will see significant growth during the period 2012-2022. Growth will be driven primarily by the increasing prevalence of arthritic conditions such as, osteoarthritis and osteoporosis. info@visiongain.com (visiongain) Fri, 20 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/805/Single-Use-Bioreactors-for-Pharma-World-Market-2012-2022 http://www.visiongain.com/Report/805/Single-Use-Bioreactors-for-Pharma-World-Market-2012-2022 pharma What does the future hold for single-use bioreactor technologies? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. Biological drugs - novel and follow-on biologics (biosimilars) - are changing pharma and supporting industries. How will bioreactor manufacturers and related suppliers seize opportunities from 2012 to 2022? Our investigation gives you business research and analysis with sales forecasts. info@visiongain.com (visiongain) Wed, 18 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/800/Smoking-Cessation-Drugs-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/800/Smoking-Cessation-Drugs-World-Market-Prospects-2012-2022 pharma What are the commercial prospects for anti-smoking treatments? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. Our investigation gives you business research and analysis with sales forecasts. It lets you assess forecasted sales at world market, submarket, product and national level to 2022. You find analysis of prescription (Rx) and over-the-counter (OTC) therapies for smoking. How will leading products - including Nicorette, Nicotinell and Champix/Chantix - perform from 2012? info@visiongain.com (visiongain) Mon, 16 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/798/Biosimilars-and-Follow-On-Biologics-World-Market-2012-2022 http://www.visiongain.com/Report/798/Biosimilars-and-Follow-On-Biologics-World-Market-2012-2022 pharma What are the commercial prospects for biosimilar drugs? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. This study investigates biosimilars (follow-on biologics). It lets you assess forecasted sales at world market, therapeutic submarket and national level to 2022. The new report gives you coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs. info@visiongain.com (visiongain) Tue, 03 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/796/Computed-Tomography-(CT)-Systems-Global-Market-Outlook-2012-2022 http://www.visiongain.com/Report/796/Computed-Tomography-(CT)-Systems-Global-Market-Outlook-2012-2022 pharma Our new report Computed Tomography (CT) Systems: Global Market Outlook 2012-2022 covers the trends in the CT systems market, a promising segment of the diagnostic imaging industry. In addition to the CT, the diagnostic imaging industry comprises of technology such as the magnetic resonance imaging (MRI) scans, X-ray, ultrasound and nuclear medicine. Computed Tomography (CT) segment is expected to witness growth driven by the advances in technology and increasing global prevalence of diseases such as cancer. According to our latest pharma report - the global CT systems market will be worth $8.6bn by 2022. info@visiongain.com (visiongain) Mon, 02 Apr 2012 00:00:00 GMT http://www.visiongain.com/Report/793/Magnetic-Resonance-Imaging-(MRI)-Systems-Global-Market-Outlook-2012-2022 http://www.visiongain.com/Report/793/Magnetic-Resonance-Imaging-(MRI)-Systems-Global-Market-Outlook-2012-2022 pharma Our new report Magnetic Resonance Imaging (MRI) Systems: Global Market Outlook 2012-2022 covers the trends in the MRI systems market, a promising segment of the diagnostic imaging industry. In addition to the MRI, the diagnostic imaging industry comprises of technology such as the computed tomography (CT) scans, X-ray, ultrasound and nuclear medicine. Magnetic Resonance Imaging (MRI) represents the fastest growing segment of the global medical imaging market, where in response to patient demand, hospitals and healthcare care providers around the world are upgrading their older equipment with state of the art systems. According to our latest pharma report - the global MRI systems market will be worth $10.4bn by 2022. info@visiongain.com (visiongain) Thu, 29 Mar 2012 00:00:00 GMT http://www.visiongain.com/Report/792/Pharma-Leader-Series-Top-50-Generic-Drug-Manufacturers-2012-2022 http://www.visiongain.com/Report/792/Pharma-Leader-Series-Top-50-Generic-Drug-Manufacturers-2012-2022 pharma How are companies in the generics market performing? Visiongain's report gives you data, analyses and discussions for leading manufacturers of generic drugs. See how generics manufacturers compare, finding out how they can compete from 2012. Our investigation gives you business research and analysis, including revenue forecasts to 2022. You discover commercial data, predictions and discussions for companies and the market in which they operate. info@visiongain.com (visiongain) Mon, 26 Mar 2012 00:00:00 GMT http://www.visiongain.com/Report/784/Ophthalmic-Drugs-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/784/Ophthalmic-Drugs-World-Market-Prospects-2012-2022 pharma What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions. How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks. info@visiongain.com (visiongain) Fri, 16 Mar 2012 00:00:00 GMT http://www.visiongain.com/Report/780/Orthobiologics-Global-Market-Prospects-2012-2022 http://www.visiongain.com/Report/780/Orthobiologics-Global-Market-Prospects-2012-2022 pharma Our new report Orthobiologics: Global Market Prospects 2012-2022 covers the trends in the orthobiologics market, a promising segment of the orthopaedic sector. The orthobiologics market will see significant growth during the period 2012-2022. Growth will be driven primarily by the increasing prevalence of arthritic conditions such as, osteoarthritis and osteoporosis. In addition, an increase in demand for minimally invasive products that offer improved comfort and durability will further drive growth of this market. info@visiongain.com (visiongain) Wed, 07 Mar 2012 00:00:00 GMT http://www.visiongain.com/Report/778/Diabetes-Treatments-World-Drug-Market-2012-2022 http://www.visiongain.com/Report/778/Diabetes-Treatments-World-Drug-Market-2012-2022 pharma What does the future hold for diabetes treatments? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. The study investigates drugs to treat human diabetes. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022. How will 23 leading products - including Lantus, Humalog, Actos and Byetta - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. info@visiongain.com (visiongain) Tue, 06 Mar 2012 00:00:00 GMT http://www.visiongain.com/Report/770/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022 http://www.visiongain.com/Report/770/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022 pharma Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022. How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs. info@visiongain.com (visiongain) Fri, 24 Feb 2012 00:00:00 GMT http://www.visiongain.com/Report/767/Infusion-Pumps-Technology-and-Market-2012-2022 http://www.visiongain.com/Report/767/Infusion-Pumps-Technology-and-Market-2012-2022 pharma Our new report Infusion Pumps: Technology and Market 2012-2022 covers the trends in the infusion pumps market, a promising segment of the drug delivery sector. The traditional gravity controlled infusion pumps have been used extensively. The electronic infusion pumps have also been available in the market since long, but only beginning to see increased adoption. The use of infusion pumps is advantageous for the healthcare providers as well as the patients specifically for conditions such as diabetes, delivery of analgesics in cancer patients or post-surgery, delivery of chemotherapy drugs and enteral feeding in patients with feeding disorders. info@visiongain.com (visiongain) Thu, 16 Feb 2012 00:00:00 GMT http://www.visiongain.com/Report/765/Pharma-Leader-Series-Top-Pre-Filled-Injection-Device-Manufacturers-2012-2022 http://www.visiongain.com/Report/765/Pharma-Leader-Series-Top-Pre-Filled-Injection-Device-Manufacturers-2012-2022 pharma How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices. That new study lets you assess prominent companies in the pre-filled (ready-to-fill) syringe industry and market from 2012 to 2022. info@visiongain.com (visiongain) Wed, 15 Feb 2012 00:00:00 GMT http://www.visiongain.com/Report/764/World-Biological-Drugs-Market-2012-2022 http://www.visiongain.com/Report/764/World-Biological-Drugs-Market-2012-2022 pharma Where is the market for biological drugs heading? Our new study investigates biotechnology in pharma - biological drugs (biopharmaceuticals, biologics). It lets you assess potential sales trends at world market, submarket, product and regional level to 2022. How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. info@visiongain.com (visiongain) Tue, 14 Feb 2012 00:00:00 GMT http://www.visiongain.com/Report/758/Drug-Delivery-Technologies-Commercial-Prospects-2012-2022 http://www.visiongain.com/Report/758/Drug-Delivery-Technologies-Commercial-Prospects-2012-2022 pharma What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. This decade, many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2022 at world market, submarket, application and national level. info@visiongain.com (visiongain) Tue, 31 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/754/Needle-Free-Delivery-Technology-and-Market-2012-2022 http://www.visiongain.com/Report/754/Needle-Free-Delivery-Technology-and-Market-2012-2022 pharma The technology and devices for needle-free delivery of drugs/vaccines has been available in the market since several decades. Although their market penetration has been low, the recent years have seen an increase in adoption, driven by the need for pain free delivery. Currently, the market for needle-free delivery devices is dominated by small medical device companies and academic researchers. These small scale companies are developing innovative needle-free delivery technologies, with the pharmaceutical companies entering into partnership with the device developers for using the technology for delivery of the company's drug. info@visiongain.com (visiongain) Tue, 24 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/753/Cell-Based-Assays-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/753/Cell-Based-Assays-World-Market-Prospects-2012-2022 pharma What does the future hold for cell-based assays in pharma? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Our study analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organisations. You discover sales predictions to 2022 at world market, main submarket and national levels. info@visiongain.com (visiongain) Mon, 23 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/746/Dermatological-Drugs-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/746/Dermatological-Drugs-World-Market-Prospects-2012-2022 pharma Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study assesses drugs to treat human skin disorders. You discover sales predictions at world market, therapeutic submarket, product and national levels to 2022. How will 24 leading drugs - Valtrex, Zovirax, Protopic, Enbrel and others - perform from 2012? Our report gives you business research and analysis with many sales forecasts. info@visiongain.com (visiongain) Wed, 18 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/744/Endoscopy-Devices-World-Market-Outlook-2012-2022 http://www.visiongain.com/Report/744/Endoscopy-Devices-World-Market-Outlook-2012-2022 pharma How will the endoscopy devices market perform from 2012? Our new report shows you potential sales and trends to 2022, discussing opportunities and prospects. See sales predictions and discussions for the leading segments in the endoscopy device market, including laparoscopy, urology, and gastrointestinal endoscopy devices markets. info@visiongain.com (visiongain) Wed, 11 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/743/Antithrombotic-Anticoagulant-Drugs-World-Market-2012-2022 http://www.visiongain.com/Report/743/Antithrombotic-Anticoagulant-Drugs-World-Market-2012-2022 pharma Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022. info@visiongain.com (visiongain) Tue, 10 Jan 2012 00:00:00 GMT http://www.visiongain.com/Report/739/Point-of-Care-Diagnostics-World-Market-Outlook-2012-2021 http://www.visiongain.com/Report/739/Point-of-Care-Diagnostics-World-Market-Outlook-2012-2021 pharma How will the point of care diagnostics market perform from 2011? Our new report shows you potential sales and trends to 2021, discussing opportunities and prospects. Discover sales for the point of care diagnostics market at segment and national/regional levels. info@visiongain.com (visiongain) Fri, 23 Dec 2011 00:00:00 GMT http://www.visiongain.com/Report/734/Biobanking-for-Medicine-Technology-and-Market-2012-2022 http://www.visiongain.com/Report/734/Biobanking-for-Medicine-Technology-and-Market-2012-2022 pharma What does the future hold for biobanks? Visiongain's report shows you potential revenues and trends to 2022. Find data, forecasts and discussions for biobanking in medicine. Discover sales predictions at overall market, submarket and national levels to 2022. Our study gives you business research, analysis and opinion for applications in medical research, pharmaceuticals and diagnostics. info@visiongain.com (visiongain) Tue, 13 Dec 2011 00:00:00 GMT http://www.visiongain.com/Report/728/Cardiac-Rhythm-Management-Devices-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/728/Cardiac-Rhythm-Management-Devices-World-Market-Outlook-2011-2021 pharma How will the cardiac rhythm management devices market perform from 2011? Discover sales for implantable cardioverter defibrillator devices, pacemakers, cardiac resynchronisation therapy devices and cardiac ablation market at segment and national levels. Our report gives you business research, analysis and data. info@visiongain.com (visiongain) Wed, 07 Dec 2011 00:00:00 GMT http://www.visiongain.com/Report/726/Chinese-Pharmaceutical-Market-2012-2022 http://www.visiongain.com/Report/726/Chinese-Pharmaceutical-Market-2012-2022 pharma Where is the pharma market in China heading? Discover sales predictions at overall market and submarket levels. See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs. info@visiongain.com (visiongain) Tue, 06 Dec 2011 00:00:00 GMT http://www.visiongain.com/Report/724/Antibacterial-Drugs-World-Market-Prospects-2012-2022 http://www.visiongain.com/Report/724/Antibacterial-Drugs-World-Market-Prospects-2012-2022 pharma What are the commercial prospects for antibacterial treatments? Discover sales predictions at world market, therapeutic class, product and national levels to 2022. How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? info@visiongain.com (visiongain) Mon, 28 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/723/Multiple-Sclerosis-Treatment-World-Drug-Market-2012-2022 http://www.visiongain.com/Report/723/Multiple-Sclerosis-Treatment-World-Drug-Market-2012-2022 pharma What are the commercial prospects for multiple sclerosis treatment? Discover revenue predictions for multiple sclerosis (MS) treatments at world market, product and national levels to 2022. How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya perform to 2022? info@visiongain.com (visiongain) Wed, 23 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/719/Medical-Device-Contract-Manufacturing-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/719/Medical-Device-Contract-Manufacturing-World-Market-Prospects-2011-2021 pharma The medical device industry has witnessed explosive growth in recent years. According to visiongain estimates, the global market was worth $236.1bn in 2010. Much of this growth is linked to the rising prevalence of diseases worldwide, most notably cardiac and neurological disorders. As most of the prominent companies in the industry operate globally, the growth of the industry is highly dependent on the economic conditions prevailing in the international market. As a result, the industry was not immune to the recent global recession and faced numerous issues including price/volume concerns, healthcare reforms and a more restrictive regulatory environment. info@visiongain.com (visiongain) Mon, 21 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/716/Advanced-Wound-Care-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/716/Advanced-Wound-Care-World-Market-Prospects-2011-2021 pharma The wound care devices and biologics segment within the advanced wound care market are set for rapid growth over the next ten years. The growth in the market will be driven primarily by the increasing prevalence of diabetes and obesity, coupled with the aging population, which will increase the incidence of chronic wounds. The adoption of expensive but more effective wound care devices and biologics will increase in the developed countries in the near future. Visiongain calculates the total advanced wound care market to be worth $6.7bn in 2011. info@visiongain.com (visiongain) Fri, 11 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/712/Next-Generation-Antibody-Therapies-Pipeline-and-Market-2011-2021 http://www.visiongain.com/Report/712/Next-Generation-Antibody-Therapies-Pipeline-and-Market-2011-2021 pharma What are the prospects for emerging antibody technologies? Visiongain's report shows you potential revenues to 2021, discussing R&D trends and opportunities. A new generation of therapeutic antibody is coming. Discover revenue predictions for emerging antibody technologies at total world and submarket levels to 2021. info@visiongain.com (visiongain) Tue, 08 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/708/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021 http://www.visiongain.com/Report/708/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021 pharma What does the future hold for small-molecule cancer treatments? Find revenue predictions at overall world market, product and national levels to 2021. Where are the 10 leading drugs heading? Find out how products such as Glivec/Gleevec, Revlimid, Alimta, Taxotere, Velcade and Tarceva can perform to 2021. See potential revenues and other trends. info@visiongain.com (visiongain) Tue, 01 Nov 2011 00:00:00 GMT http://www.visiongain.com/Report/701/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/701/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2011-2021 pharma What are the prospects for epigenetic products and technologies? Visiongain's report shows you potential revenues to 2021, discussing trends and opportunities. Where is the epigenetics market heading? Find revenue predictions for epigenetic applications at total world, submarket, product and national levels to 2021. info@visiongain.com (visiongain) Mon, 17 Oct 2011 00:00:00 GMT http://www.visiongain.com/Report/695/Vaccine-Manufacturing-Technology-and-Services-World-Market-2011-2021 http://www.visiongain.com/Report/695/Vaccine-Manufacturing-Technology-and-Services-World-Market-2011-2021 pharma What does the future hold for the vaccine manufacturing industry and market? Visiongain's report shows you potential revenues and trends to 2021. Discover activities shaping the vaccines market and the outsourcing of vaccine manufacturing for human healthcare. Vaccine manufacturing will become more important this decade. Our study discusses activities of GSK, Sanofi, Merck & Co., Novartis, Pfizer and others. See how changes in the pharma industry affect production, outsourcing and contract service providers (CMOs). info@visiongain.com (visiongain) Thu, 06 Oct 2011 00:00:00 GMT http://www.visiongain.com/Report/693/Neuromodulation-Devices-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/693/Neuromodulation-Devices-World-Market-Prospects-2011-2021 pharma Our latest pharma report - Neuromodulation Devices: World Market Prospects 2011-2021 - offers a comprehensive view of the global neuromodulation devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the neuromodulation devices market in 2011 to be worth $3.05bn. info@visiongain.com (visiongain) Wed, 05 Oct 2011 00:00:00 GMT http://www.visiongain.com/Report/691/World-Pharma-Contract-Sales-Organisation-(CSO)-Market-2011-2021 http://www.visiongain.com/Report/691/World-Pharma-Contract-Sales-Organisation-(CSO)-Market-2011-2021 pharma How will the pharma contract sales market perform from 2011? Visiongain's report shows you potential revenues and trends to 2021, discussing opportunities and prospects. Our report gives you forecasts to 2021 for the world market and leading countries. Outsourced pharma sales activities will expand from 2011 to 2021. See how emerging technologies are changing drug promotion and sales, and how service providers contribute value to pharmaceutical sales operations. info@visiongain.com (visiongain) Fri, 30 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/689/Parkinson's-Disease-World-Drug-Market-2011-2021 http://www.visiongain.com/Report/689/Parkinson's-Disease-World-Drug-Market-2011-2021 pharma What are the commercial prospects for the treatment of Parkinson's disease? Visiongain's report shows you potential drug revenues to 2021. Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can perform to 2021, seeing potential revenues. We cover revenues for dopaminergic agents, dopamine agonists, COMT inhibitors, MAO inhibitors and other drugs for Parkinson's disease. info@visiongain.com (visiongain) Mon, 26 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/685/Therapeutic-Monoclonal-Antibodies-World-Market-2011-2021 http://www.visiongain.com/Report/685/Therapeutic-Monoclonal-Antibodies-World-Market-2011-2021 pharma How will the market for monoclonal antibody (mAb) therapies perform from 2011? How will competition affect the mAb industry and market? Which national markets have the greatest potential for growth? Discover mAb treatment revenues at total world, submarket, product and national levels. The monoclonal antibody drug market has potential to expand. See how treatments such as Avastin, Herceptin, MabThera, Remicade, Humira, Tysabri and Lucentis can perform to 2021. info@visiongain.com (visiongain) Mon, 19 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/682/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/682/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021 pharma Our latest pharma report - Interventional Cardiology Devices: World Market Prospects 2011-2021 - offers a comprehensive view of the global interventional cardiology devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. Visiongain analyses predict the global value of the interventional cardiology devices market in 2011 to be worth $10.6bn. Growth in this market will be driven by new technology such as, bioabsorbable stents, drug-eluting balloons and optical coherence tomography. info@visiongain.com (visiongain) Fri, 16 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/681/Generic-Drugs-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/681/Generic-Drugs-World-Market-Outlook-2011-2021 pharma How will the market for generic drugs perform from 2011? Visiongain's report shows you potential revenues to 2021. The world generics market has great potential to expand. Discover generic drug market revenues at total world and national levels. Which national markets have the greatest potential? See how generics markets in the US, Japan, leading EU countries, India, China, Turkey, Brazil, Mexico, South Korea and the Russian Federation can perform to 2021. info@visiongain.com (visiongain) Tue, 13 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021 http://www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021 pharma How will the market for rheumatoid arthritis treatments perform from 2011? Visiongain's report shows you potential revenues to 2021, discussing opportunities and prospects. Discover rheumatoid arthritis drug revenues at total world, submarket, product and national levels. info@visiongain.com (visiongain) Wed, 07 Sep 2011 00:00:00 GMT http://www.visiongain.com/Report/674/Pharmacovigilance-and-Related-Developments-2011-2021 http://www.visiongain.com/Report/674/Pharmacovigilance-and-Related-Developments-2011-2021 pharma What does the future hold for pharmacovigilance? Visiongain's new report shows you prospects to 2021, discussing opportunities and developments. Find data you need. Assess events, opportunities and activities shaping pharmacovigilance to 2021: regulations, technologies and services. How will changes affect pharmacovigilance? What are drug producers and service providers doing? What regulations and technologies influence that field? info@visiongain.com (visiongain) Mon, 22 Aug 2011 00:00:00 GMT http://www.visiongain.com/Report/675/Companion-Diagnostics-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/675/Companion-Diagnostics-World-Market-Outlook-2011-2021 pharma Our latest pharma report - Companion Diagnostics: World Market Outlook 2011-2021 - offers a comprehensive view of the global companion diagnostics market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the companion diagnostics market in 2011 to be worth $1.57bn. A number of specialty drugs will be associated with a companion diagnostic test by 2021, increasing the global market for companion diagnostics. info@visiongain.com (visiongain) Mon, 22 Aug 2011 00:00:00 GMT http://www.visiongain.com/Report/663/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/663/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2011-2021 pharma The pharmaceutical manufacturing market refers to the outsourcing of pharmaceutical product manufacturing to contract manufacturing organisations (CMOs) by pharmaceutical companies. Major pharmaceutical companies use CMOs principally to achieve efficiencies in cost, capacity, and time-to-market, or to obtain a specific expertise not available in-house. In the past, outsourcing manufacturing was a tactical decision for pharmaceutical companies - they outsourced to fill short-term lack of capacity or personnel. However, in the past decade, there has been a move towards more strategic outsourcing. Companies now look to outsource manufacturing so that they can focus on their core competencies, freeing up personnel and capital that have otherwise been invested in running manufacturing facilities. info@visiongain.com (visiongain) Thu, 11 Aug 2011 00:00:00 GMT http://www.visiongain.com/Report/658/Asthma-and-COPD-Therapies-World-Market-2011-2021 http://www.visiongain.com/Report/658/Asthma-and-COPD-Therapies-World-Market-2011-2021 pharma How will the market for asthma and COPD treatments perform from 2011? Discover potential asthma and COPD drug revenues at total world, company, product and national levels. How will competition affect the asthma and COPD treatment market? We show you how drugs such as Seretide/Advair, Singulair, Spiriva, Symbicort, Combivent and Pulmicort can perform to 2021. info@visiongain.com (visiongain) Mon, 08 Aug 2011 00:00:00 GMT http://www.visiongain.com/Report/652/Translational-Regenerative-Medicine-Market-Prospects-2011-2021 http://www.visiongain.com/Report/652/Translational-Regenerative-Medicine-Market-Prospects-2011-2021 pharma What are the commercial prospects for regenerative medicine? Our new report shows you potential revenues to 2021, discussing opportunities and market prospects. Our study identifies three main areas: tissue engineering, stem cell therapy and gene therapy. info@visiongain.com (visiongain) Wed, 27 Jul 2011 00:00:00 GMT http://www.visiongain.com/Report/650/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021 http://www.visiongain.com/Report/650/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021 pharma How will the market for inflammatory bowel disease (IBD) treatments perform from 2011? Our new report shows you potential pharmaceutical revenues to 2021, discussing opportunities and market prospects. info@visiongain.com (visiongain) Mon, 25 Jul 2011 00:00:00 GMT http://www.visiongain.com/Report/647/Drug-Discovery-Outsourcing-World-Market-2011-2021 http://www.visiongain.com/Report/647/Drug-Discovery-Outsourcing-World-Market-2011-2021 pharma How will the drug discovery outsourcing market develop this decade? Assess the activities shaping drug discovery outsourcing worldwide. How will changes in focus for pharmaceutical R&D affect drug discovery outsourcing and contract research organisations? Which preclinical activities, technologies and national markets will provide the best opportunities from 2011 to 2021? info@visiongain.com (visiongain) Fri, 15 Jul 2011 00:00:00 GMT http://www.visiongain.com/Report/642/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-(DR)-World-Drug-Market-2011-2021 http://www.visiongain.com/Report/642/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-(DR)-World-Drug-Market-2011-2021 pharma What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? Our new report shows you potential revenues to 2021, discussing commercial opportunities and prospects. Discover potential revenues at total world, submarket, product and national levels. info@visiongain.com (visiongain) Fri, 08 Jul 2011 00:00:00 GMT http://www.visiongain.com/Report/641/Pharma-Clinical-Trial-Services-World-Market-2011-2021 http://www.visiongain.com/Report/641/Pharma-Clinical-Trial-Services-World-Market-2011-2021 pharma How will the clinical trial services industry perform from 2011 onwards? Our new report shows you potential revenues and trends to 2021, discussing opportunities and prospects. How will changes in focus for pharmaceutical R&D affect clinical outsourcing and CROs? Which research areas and national markets will provide the best opportunities to 2021? info@visiongain.com (visiongain) Mon, 04 Jul 2011 00:00:00 GMT http://www.visiongain.com/Report/633/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021 http://www.visiongain.com/Report/633/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021 pharma What are the commercial prospects for lyophilisation technology? Our new report shows you potential revenues to 2021. Our report covers lyophilisation (cryodesiccation or freeze drying) in pharmaceutical applications: technologies, products and services. You will assess events, opportunities and activities shaping the lyophilisation industry and market from 2011 to 2021. info@visiongain.com (visiongain) Mon, 27 Jun 2011 00:00:00 GMT http://www.visiongain.com/Report/632/Biomarkers-Technological-and-Commercial-Outlook-2011-2021 http://www.visiongain.com/Report/632/Biomarkers-Technological-and-Commercial-Outlook-2011-2021 pharma What are the commercial prospects for biomarkers in pharma and diagnostics? In our study you will find discussions of genomic and proteomic approaches to biomarker discovery, including metabolomics and microarray platforms. You will see how biomarker technologies are changing pharma and diagnostics. info@visiongain.com (visiongain) Wed, 22 Jun 2011 00:00:00 GMT http://www.visiongain.com/Report/631/Pre-Filled-Syringes-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/631/Pre-Filled-Syringes-World-Market-Outlook-2011-2021 pharma How will the pre-filled syringes market develop this decade? prospects. Our report covers pre-filled syringes in therapeutic applications: devices and drugs. You will find potential revenues for pre-filled syringe technologies at total world, submarket and national levels to 2021. What technologies and applications will expand that market? info@visiongain.com (visiongain) Tue, 21 Jun 2011 00:00:00 GMT http://www.visiongain.com/Report/629/In-Vitro-Diagnostics-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/629/In-Vitro-Diagnostics-World-Market-Outlook-2011-2021 pharma How will the in vitro diagnostics (IVD) market develop this decade? Our report shows you potential revenues to 2021, discussing opportunities and prospects. Through our research and analysis we aim to save you time and help in your decisions. Our new study shows you potential revenues to 2021 for in vitro diagnostics at total world, submarket and national levels. What technologies and applications will expand that market? What effects will changes have? You will find predictions and answers. info@visiongain.com (visiongain) Mon, 13 Jun 2011 00:00:00 GMT http://www.visiongain.com/Report/627/World-Vaccines-Market-2011-2021 http://www.visiongain.com/Report/627/World-Vaccines-Market-2011-2021 pharma Do you want to know how the vaccines industry and market will develop from 2011? Our new report shows you potential revenues to 2021, discussing opportunities and prospects. You will find revenue predictions at total world, submarket, product, company and national levels. You will see how products such as Prevnar, Pandemrix, Fluzone, Proquad/MMR-II/Varivax, Infanrix/Pediarix and Gardasil can perform to 2021. info@visiongain.com (visiongain) Tue, 07 Jun 2011 00:00:00 GMT http://www.visiongain.com/Report/616/Single-Use-Bioreactors-for-Pharma-World-Market-2011-2021 http://www.visiongain.com/Report/616/Single-Use-Bioreactors-for-Pharma-World-Market-2011-2021 pharma How will the market for single-use bioreactors develop this decade? Our study shows you revenue prospects for disposable bioreactor technology at total world, submarket and national levels to 2021. You will discover commercial prospects, including those for hardware, disposable bags, accessories and specialist products and services. info@visiongain.com (visiongain) Wed, 18 May 2011 00:00:00 GMT http://www.visiongain.com/Report/612/Stem-Cell-Technologies-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/612/Stem-Cell-Technologies-World-Market-Outlook-2011-2021 pharma How will the stem cells market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021. This report covers stem cells in therapeutic applications: technologies, products and services. You will assess events, opportunities and activities shaping that industry. Our new study shows you revenue prospects for stem cells at total world, submarket and product levels to 2021. What activities will expand that market from 2011 to 2021? info@visiongain.com (visiongain) Tue, 10 May 2011 00:00:00 GMT http://www.visiongain.com/Report/610/Acute-Coronary-Syndrome-(ACS)-Drug-Market-Prospects-2011-2021 http://www.visiongain.com/Report/610/Acute-Coronary-Syndrome-(ACS)-Drug-Market-Prospects-2011-2021 pharma What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021. info@visiongain.com (visiongain) Fri, 06 May 2011 00:00:00 GMT http://www.visiongain.com/Report/609/Genomic-Sequencing-Technologies-for-Medicine-Market-Prospects-2011-2021 http://www.visiongain.com/Report/609/Genomic-Sequencing-Technologies-for-Medicine-Market-Prospects-2011-2021 pharma How will the genomic sequencing market develop this decade? This report covers technology to support genomics, with an emphasis on pharma R&D. Our new study shows you revenue prospects for genomic technologies at total world, submarket, company and national levels to 2021. Third-generation sequencing platforms can increase throughput and lower costs. info@visiongain.com (visiongain) Tue, 03 May 2011 00:00:00 GMT http://www.visiongain.com/Report/606/World-Pain-Relieving-Drug-Market-2011-2021 http://www.visiongain.com/Report/606/World-Pain-Relieving-Drug-Market-2011-2021 pharma What are the prospects for the pain treatment market from 2011? Our new report shows you its revenue potential from 2011 to 2021. Our report gives you revenue forecasts to 2021 for pain-relieving drugs. You will discover market predictions at total world, submarket, product and national levels. info@visiongain.com (visiongain) Wed, 27 Apr 2011 00:00:00 GMT http://www.visiongain.com/Report/603/World-Multiple-Myeloma-Drug-Treatment-Market-2011-2021 http://www.visiongain.com/Report/603/World-Multiple-Myeloma-Drug-Treatment-Market-2011-2021 pharma What are the prospects for the multiple myeloma treatment market from 2011? Our new report shows you its revenue potential from 2011 to 2021. Our report gives you revenue forecasts to 2021 for myeloma drugs. You will discover market predictions at total world, product and national levels. info@visiongain.com (visiongain) Fri, 15 Apr 2011 00:00:00 GMT http://www.visiongain.com/Report/598/Pharmaceutical-Anti-counterfeiting-Technologies-Market-Analysis-2011-2021 http://www.visiongain.com/Report/598/Pharmaceutical-Anti-counterfeiting-Technologies-Market-Analysis-2011-2021 pharma What are the commercial prospects for pharmaceutical anti-counterfeiting technology? Our new report shows you that industry and market's revenue potential from 2011 to 2021. Our report shows you revenue prospects for pharma anti-counterfeiting technologies at total world, submarket and national levels to 2021. We discuss the anti-counterfeiting activities of companies such as Pfizer, J&J, GSK, Sanofi-Aventis, Novartis and AstraZeneca. info@visiongain.com (visiongain) Mon, 11 Apr 2011 00:00:00 GMT http://www.visiongain.com/Report/601/Biosimilars-and-Follow-On-Biologics-World-Market-2011-2021 http://www.visiongain.com/Report/601/Biosimilars-and-Follow-On-Biologics-World-Market-2011-2021 pharma How will the biosimilars and follow-on biologics market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021. This report covers drugs in the biosimilar medicinal product and follow-on protein product field. You will assess events, opportunities and activities shaping that industry. info@visiongain.com (visiongain) Mon, 11 Apr 2011 00:00:00 GMT http://www.visiongain.com/Report/595/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021 http://www.visiongain.com/Report/595/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021 pharma How will the pharma wholesale and distribution industry perform from 2011 onwards? What effects will healthcare budget cuts have on pharmaceutical wholesalers? Which national markets will provide the best opportunities from 2011 to 2021? How common will direct-to-pharmacy distribution become? Our work provides answers you need. info@visiongain.com (visiongain) Fri, 01 Apr 2011 00:00:00 GMT http://www.visiongain.com/Report/590/RNAi-for-Therapeutic-Applications-Market-Prospects-2011-2021 http://www.visiongain.com/Report/590/RNAi-for-Therapeutic-Applications-Market-Prospects-2011-2021 pharma How will the RNA interference (RNAi) therapies market develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021. Our new study shows you revenue prospects for RNAi technologies at total world, geographical and product levels. We discuss RNAi applications for cancer, respiratory disorders, eye disorders and other diseases. info@visiongain.com (visiongain) Tue, 29 Mar 2011 00:00:00 GMT http://www.visiongain.com/Report/586/Ophthalmic-Drugs-World-Market-2011-2021 http://www.visiongain.com/Report/586/Ophthalmic-Drugs-World-Market-2011-2021 pharma Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. You will discover revenue prospects for eye disorder drugs at total world, sub-market, product and national levels. We cover drugs for glaucoma, retinal disorders, dry eye, ocular allergy, inflammation and infection. info@visiongain.com (visiongain) Fri, 18 Mar 2011 00:00:00 GMT http://www.visiongain.com/Report/585/World-Diabetes-Drug-Market-2011-2021 http://www.visiongain.com/Report/585/World-Diabetes-Drug-Market-2011-2021 pharma Where will revenue growth occur in the diabetes treatment market? Our new report shows you the potential that drug market offers from 2011 to 2021, explaining the opportunities there. You will discover revenue prospects for diabetes treatments at total world, sub-market, product and national levels. We show potential revenues for human insulins and analogues, as well as other diabetes treatments. You will discover revenue prospects for Novo Nordisk, GSK, Takeda, sanofi-aventis, Eli Lilly, Merck and other companies from 2011 onwards. info@visiongain.com (visiongain) Fri, 11 Mar 2011 00:00:00 GMT http://www.visiongain.com/Report/581/Statins-World-Market-Outlook-2011-2021 http://www.visiongain.com/Report/581/Statins-World-Market-Outlook-2011-2021 pharma What does the future hold for the statins industry and market? Our new report shows how the patent expiry of Lipitor and others will affect statin drug revenues from 2011 onwards. In 2009 the world statins market generated over $27bn in revenues. We show the organisations, products and activities that will shape the statins industry and market this decade. info@visiongain.com (visiongain) Thu, 03 Mar 2011 00:00:00 GMT http://www.visiongain.com/Report/578/Leading-Anti-Cancer-Drugs-World-Market-Prospects-2011-2021 http://www.visiongain.com/Report/578/Leading-Anti-Cancer-Drugs-World-Market-Prospects-2011-2021 pharma What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. Anti-cancer drug sales exceeded $50bn worldwide in 2009, with impressive growth. Our report shows you where cancer therapies are heading from 2011 to 2021 - technology, competition and revenues. info@visiongain.com (visiongain) Fri, 25 Feb 2011 00:00:00 GMT http://www.visiongain.com/Report/575/World-Anti-Obesity-Drug-Market-2011-2021 http://www.visiongain.com/Report/575/World-Anti-Obesity-Drug-Market-2011-2021 pharma What will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level. How will the regulatory and marketing difficulties facing anti-obesity drugs affect companies and their revenues? In our report you will see prospects for obesity drug research, development, launches and marketing from 2011 onwards. info@visiongain.com (visiongain) Mon, 21 Feb 2011 00:00:00 GMT http://www.visiongain.com/Report/573/World-Biological-Drugs-Market-2011-2021 http://www.visiongain.com/Report/573/World-Biological-Drugs-Market-2011-2021 pharma Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. What revenues will biopharmaceutical markets achieve from 2011 to 2021? What gains can leading companies achieve? What sales trends will national markets - developed and developing - show? info@visiongain.com (visiongain) Wed, 09 Feb 2011 00:00:00 GMT http://www.visiongain.com/Report/572/World-Influenza-Vaccines-Market-2011-2021 http://www.visiongain.com/Report/572/World-Influenza-Vaccines-Market-2011-2021 pharma Are you looking for influenza vaccine market data - answers to benefit your work? Our new report shows you revenue prospects for the manufacture and sale of influenza vaccines from 2009 to 2021. info@visiongain.com (visiongain) Mon, 07 Feb 2011 00:00:00 GMT http://www.visiongain.com/Report/562/Cell-Based-Assays-World-Market-Prospects-2011-2026 http://www.visiongain.com/Report/562/Cell-Based-Assays-World-Market-Prospects-2011-2026 pharma Are you looking for pharmaceutical R&D market data - answers to save you time and effort, aiding decisions? Our new report shows you spending trends and revenue prospects for cell-based assays in pharma. We give market data for 2009 to 2026. info@visiongain.com (visiongain) Wed, 19 Jan 2011 00:00:00 GMT http://www.visiongain.com/Report/559/Antibacterial-Drugs-Commercial-Prospects-2011-2026 http://www.visiongain.com/Report/559/Antibacterial-Drugs-Commercial-Prospects-2011-2026 pharma What revenues will the world antibacterial drug market yield from 2011 to 2026? What will be the revenue prospects for leading antibacterial products? What will be the sales trends for leading national markets, developed and developing? Our report answers those questions and others. You will find original sales forecasts for 2010 to 2026. info@visiongain.com (visiongain) Wed, 12 Jan 2011 00:00:00 GMT http://www.visiongain.com/Report/555/CNS-Clinical-Trials-World-Market-Prospects-2011-2026 http://www.visiongain.com/Report/555/CNS-Clinical-Trials-World-Market-Prospects-2011-2026 pharma How will the CNS clinical trials sector develop from 2010, and where can you find the greatest opportunities there? Our new report shows you prospects for revenue growth worldwide, with contract research providers and sponsors of CNS clinical trials analysed. Investment in R&D for central nervous system disorders comes second only to that of oncology. We show how you could make gains in the CNS sector, especially for treating neurological disorders. You can assess the potential of the industry and market now. info@visiongain.com (visiongain) Mon, 13 Dec 2010 00:00:00 GMT http://www.visiongain.com/Report/551/US-Pharmaceutical-Market-Outlook-2011-2021 http://www.visiongain.com/Report/551/US-Pharmaceutical-Market-Outlook-2011-2021 pharma Do you want to know the effects of the Obama government's legislation for US healthcare? Insurance coverage will be extended, expanding the pharma market. But at what price to the pharmaceutical industry in rebates and other costs? Will the healthcare reforms underwrite another decade of growth in the US pharma market, or has it reached its limits? US Pharmaceutical Market Outlook 2011-2021 answers those questions with a deep, wide-ranging survey of the market. info@visiongain.com (visiongain) Fri, 03 Dec 2010 00:00:00 GMT http://www.visiongain.com/Report/547/Pharmaceutical-Stability-Testing-Commercial-Prospects-2011-2025 http://www.visiongain.com/Report/547/Pharmaceutical-Stability-Testing-Commercial-Prospects-2011-2025 pharma Pharmaceutical stability testing (PST) is an important component of drug development and manufacturing. This market constitutes one of the fastest growing sectors in the pharmaceutical and biotech sectors, with estimated revenues of $0.95bn (for technology and services) in 2010. info@visiongain.com (visiongain) Wed, 24 Nov 2010 00:00:00 GMT http://www.visiongain.com/Report/543/Dermatological-Drugs-World-Market-2011-2026 http://www.visiongain.com/Report/543/Dermatological-Drugs-World-Market-2011-2026 pharma Dermatological drugs form an important segment of the global pharma market, with sales of over $25bn in 2009. New drugs with improved safety and efficacy can gain significant market shares in the future, our study reveals. info@visiongain.com (visiongain) Wed, 10 Nov 2010 00:00:00 GMT http://www.visiongain.com/Report/541/Neurodegenerative-Diseases-World-Drug-Market-2011-2026 http://www.visiongain.com/Report/541/Neurodegenerative-Diseases-World-Drug-Market-2011-2026 pharma Would you like to know how the industry and market for neurodegenerative drug treatments will develop? There will be trends to watch from 2010 onwards, especially areas of revenue growth. You can have our new report now, staying ahead, saving time and aiding your decisions. The number of patients may quadruple worldwide by 2050. Yet, there remain significant unmet needs in all sectors of the neurodegenerative treatments market. info@visiongain.com (visiongain) Tue, 02 Nov 2010 00:00:00 GMT http://www.visiongain.com/Report/536/Chinese-Pharmaceutical-Market-2010-2025 http://www.visiongain.com/Report/536/Chinese-Pharmaceutical-Market-2010-2025 pharma Our new report will show you how the Chinese pharma market will develop from 2010. We provide forecasts for the main therapeutic areas in the Chinese prescription drug market, as well as giving coverage of OTC medicines. You will find revenues for generic and original-branded medicines from 2009 to 2025. Our report also discusses companies in the sector - domestic and foreign - assessing their prospects. info@visiongain.com (visiongain) Thu, 14 Oct 2010 00:00:00 GMT http://www.visiongain.com/Report/532/Medical-Devices-Industry-and-Market-Prospects-2010-2025 http://www.visiongain.com/Report/532/Medical-Devices-Industry-and-Market-Prospects-2010-2025 pharma How will the medical devices sector develop from 2010, and where can you find opportunities? We show you prospects for technological development and revenue growth. You can have our new report today, staying ahead. info@visiongain.com (visiongain) Mon, 11 Oct 2010 00:00:00 GMT http://www.visiongain.com/Report/528/Drug-Delivery-Technologies-Commercial-Prospects-2010-2025 http://www.visiongain.com/Report/528/Drug-Delivery-Technologies-Commercial-Prospects-2010-2025 pharma How will the drug delivery sector develop from 2010, and where will you find the greatest opportunities? How will technology suppliers and drug companies benefit? We show you opportunities for revenue growth for suppliers and users of drug delivery technologies. You can have our report today, staying ahead. info@visiongain.com (visiongain) Tue, 05 Oct 2010 00:00:00 GMT http://www.visiongain.com/Report/527/Vaccines-Manufacturing-Technology-and-Services-Commercial-Prospects-2010-2025 http://www.visiongain.com/Report/527/Vaccines-Manufacturing-Technology-and-Services-Commercial-Prospects-2010-2025 pharma Our new report will show you how the industry and market for vaccines manufacturing will develop. You can indentify where the greatest opportunities will lie for human-use vaccines. There will be trends to watch from 2010 onwards, with areas of revenue growth. You can have our report today, staying ahead. Which vaccines manufacturing segments will grow fastest from 2010? What are the commercial trends to watch? How will leading companies perform? We aim to save you time and benefit your work. info@visiongain.com (visiongain) Tue, 28 Sep 2010 00:00:00 GMT http://www.visiongain.com/Report/524/Antithrombotic-Anticoagulant-Drugs-World-Market-Prospects-2010-2025 http://www.visiongain.com/Report/524/Antithrombotic-Anticoagulant-Drugs-World-Market-Prospects-2010-2025 pharma Our new report will show you how the market for antithrombotic and anticoagulant drugs will develop. You can indentify where the greatest opportunities will lie. There will be trends to watch from 2010 onwards, especially product launches and areas of revenue growth. You can have our report today, staying ahead. info@visiongain.com (visiongain) Fri, 17 Sep 2010 00:00:00 GMT http://www.visiongain.com/Report/522/World-Generic-Drug-Market-Outlook-2010-2025 http://www.visiongain.com/Report/522/World-Generic-Drug-Market-Outlook-2010-2025 pharma Our new report will show you revenue prospects for the generic drug market from 2010 onwards. Where will the best growth prospects lie, and which companies will be the biggest winners? We provide revenue trends for 2010 to 2025 and discussions to meet your needs. You can have that report today, staying ahead. info@visiongain.com (visiongain) Tue, 14 Sep 2010 00:00:00 GMT http://www.visiongain.com/Report/521/Pharmacovigilance-and-Other-Pharma-Regulatory-Developments-2010-2020 http://www.visiongain.com/Report/521/Pharmacovigilance-and-Other-Pharma-Regulatory-Developments-2010-2020 pharma What regulatory demands will pharma companies face from 2010 to 2020? Our new study will show you developments in pharma regulations - pre- and post-marketing - from 2010 onwards. How can regulatory developments help companies in the era of more-personalised medicine? You can have our report today, staying ahead. info@visiongain.com (visiongain) Thu, 09 Sep 2010 00:00:00 GMT http://www.visiongain.com/Report/516/Pharmaceutical-Contract-Manufacturing-Industry-and-Market-Prospects-2010-2025 http://www.visiongain.com/Report/516/Pharmaceutical-Contract-Manufacturing-Industry-and-Market-Prospects-2010-2025 pharma How will the contract manufacturing sector adapt to the needs of pharma from 2010 onwards? Our new report will show you trends and prospects there. How will the sector and its customers face challenges and opportunities? We show commercial benefits for the pharma contract manufacturing sector and its customers, including revenue trends for 2010-2025. You can have that report today, staying ahead. info@visiongain.com (visiongain) Thu, 26 Aug 2010 00:00:00 GMT http://www.visiongain.com/Report/513/Biobanking-for-Medical-R-D-Technology-and-Market-2010-2025 http://www.visiongain.com/Report/513/Biobanking-for-Medical-R-D-Technology-and-Market-2010-2025 pharma Biobanking for Medical R&D: Technology and Market 2010-2025 reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. Advances in genetic research, stem cell research and regenerative medicine increase the importance of biobanking, as well as its commercial potential. info@visiongain.com (visiongain) Thu, 19 Aug 2010 00:00:00 GMT http://www.visiongain.com/Report/508/Therapeutic-Monoclonal-Antibodies-World-Market-2010-2025 http://www.visiongain.com/Report/508/Therapeutic-Monoclonal-Antibodies-World-Market-2010-2025 pharma In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report. info@visiongain.com (visiongain) Tue, 03 Aug 2010 00:00:00 GMT http://www.visiongain.com/Report/502/Prospects-for-Pharma-Mergers-Acquisitions-and-Alliances-2010-2020 http://www.visiongain.com/Report/502/Prospects-for-Pharma-Mergers-Acquisitions-and-Alliances-2010-2020 pharma Last year was important for pharmaceutical mergers and acquisitions, with total deal values in 2009 reaching almost $150bn. Driving this activity were three 'mega-mergers' at the heart of the industry, as Pfizer took over Wyeth, Roche bought the remaining shares in Genentech, and Merck & Co acquired Schering-Plough. Those historic deals signal the continued importance of mergers and acquisitions (M&A) as a strategy among pharma companies, with associated benefits and challenges. The importance of consolidation and alliances will increase from 2010 onwards, as companies adapt to changing conditions within the industry and market. info@visiongain.com (visiongain) Fri, 23 Jul 2010 00:00:00 GMT http://www.visiongain.com/Report/500/The-Global-OTC-Pharmaceutical-Market-2010-2025 http://www.visiongain.com/Report/500/The-Global-OTC-Pharmaceutical-Market-2010-2025 pharma In 2009, the global over-the-counter (OTC) pharmaceutical market generated revenues of more than $60bn. Our analyses show that total OTC revenues will exceed $70bn by 2015. From 2010 onwards, Rx-to-OTC switching and the continuing importance of emerging healthcare markets will drive sales in this sector. Our forecasts reveal that the OTC pharma market will grow significantly from 2010 onwards. This report explains where future OTC switching and other developments will occur, providing you with the information that you need to understand the current OTC market and its future prospects. info@visiongain.com (visiongain) Thu, 15 Jul 2010 00:00:00 GMT http://www.visiongain.com/Report/497/Clinical-Trials-World-Market-2010-2025 http://www.visiongain.com/Report/497/Clinical-Trials-World-Market-2010-2025 pharma The market for clinical trial services has been expanding rapidly, with impressive revenue growth and expansion of the sector in recent years. Our new study shows how that sector will develop from 2010 onwards, with benefits to the pharma industry and clinical service providers. Clinical research organisations (CROs) are playing increasingly important roles in drug development worldwide, from conducting phase I trials to post-marketing studies. info@visiongain.com (visiongain) Mon, 12 Jul 2010 00:00:00 GMT http://www.visiongain.com/Report/495/Pharmaceutical-Product-Lifecycle-Management-2010-2020 http://www.visiongain.com/Report/495/Pharmaceutical-Product-Lifecycle-Management-2010-2020 pharma The pharmaceutical industry currently faces marked challenges in its long-standing business model. Product lifecycle management (PLM) is being used to maximise the revenue-generating potential of pharmaceuticals, especially in their maturity, but also earlier on. In our new report - Pharmaceutical Product Lifecycle Management 2010-2020 - we examine the PLM strategies that pharmaceutical companies are using. Those measures range from reformulations, new combinations of drugs and expanded indication ranges, to the use of alliances, licensing, mergers and acquisitions. info@visiongain.com (visiongain) Tue, 06 Jul 2010 00:00:00 GMT http://www.visiongain.com/Report/493/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-Pharmaceutical-Market-2010-2025 http://www.visiongain.com/Report/493/Macular-Degeneration-(AMD)-and-Diabetic-Retinopathy-Pharmaceutical-Market-2010-2025 pharma Our new report examines current and future prospects for the age-related macular degeneration (AMD) and diabetic retinopathy (DR) pharmaceutical markets. The global market for AMD and DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD and DR is due to aging populations worldwide and other changes. In particular, the world is facing a "diabetes epidemic", with soaring numbers of people with diabetes and related complications, including diabetic retinopathy. info@visiongain.com (visiongain) Thu, 01 Jul 2010 00:00:00 GMT http://www.visiongain.com/Report/490/Lyophilisation-for-Pharmaceuticals-Technology-and-Market-2010-2025 http://www.visiongain.com/Report/490/Lyophilisation-for-Pharmaceuticals-Technology-and-Market-2010-2025 pharma Lyophilisation (also known as freeze drying or cryodesiccation) is an operation used for the preparation of stable pharmaceutical products. The market for lyophilisation has enjoyed strong growth in recent years, driven by new products and drug classes, especially in biotechnology. In recent years, the number of such products has been growing steadily. It is predicted that half of the injectable drugs approved in the next five years will require lyophilisation. In our new report, we predict that the global lyophilisation market will grow steadily in revenue and unit sales from 2010 to 2025. info@visiongain.com (visiongain) Mon, 28 Jun 2010 00:00:00 GMT http://www.visiongain.com/Report/488/In-Vitro-Diagnostics-and-Theranostics-World-Market-Analysis-2010-2025 http://www.visiongain.com/Report/488/In-Vitro-Diagnostics-and-Theranostics-World-Market-Analysis-2010-2025 pharma Our new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Those technological solutions are playing an important role in clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Molecular diagnostic technologies are leading healthcare towards the goal of personalised medicine, to the benefit of healthcare stakeholders. Molecular diagnostic tests receive support from pharmaceutical regulators, such as the FDA. info@visiongain.com (visiongain) Tue, 22 Jun 2010 00:00:00 GMT http://www.visiongain.com/Report/487/Developments-in-Pricing-and-Reimbursement-in-Leading-Pharma-Markets-2010-2020 http://www.visiongain.com/Report/487/Developments-in-Pricing-and-Reimbursement-in-Leading-Pharma-Markets-2010-2020 pharma The global economic crisis and rising healthcare costs have caused governments to take cautious approaches towards pricing and reimbursement (P&R) for pharmaceuticals. Increasing drug prices and rising demand for the latest treatments - driven by aging, expanding populations and improving standards of living - have increased the burden on healthcare systems, public and private. Those events have particularly affected countries whose healthcare is mostly funded by the state. Developing nations are also finding it challenging to meet the increasing expectations for healthcare, despite rapid economic growth. Our new report covers pharma pricing and reimbursement in detail, showing the implications of P&R developments on the pharma industry and market in leading countries. info@visiongain.com (visiongain) Mon, 21 Jun 2010 00:00:00 GMT http://www.visiongain.com/Report/485/Monoclonal-Antibodies-in-Cancer-Therapy-World-Market-Prospects-2010-2025 http://www.visiongain.com/Report/485/Monoclonal-Antibodies-in-Cancer-Therapy-World-Market-Prospects-2010-2025 pharma In 2009, monoclonal antibodies for cancer therapy generated total revenues of over $18bn worldwide. From 2010, that sector will benefit from new drugs and expanding indications for existing products. Cancer incidence and prevalence are rising worldwide; studies reveal that incidence will rise by up to 40% by 2025. Worldwide, the treatment of cancer is a priority for healthcare providers, with high demand for efficacious and well-tolerated therapies. Where is the monoclonal antibody therapy market for cancer heading - technologically and commercially - from 2010 onwards? Our new report covers such questions, providing the information that you need. info@visiongain.com (visiongain) Mon, 14 Jun 2010 00:00:00 GMT http://www.visiongain.com/Report/482/Breast-Cancer-Drugs-World-Market-Prospects-2010-2025 http://www.visiongain.com/Report/482/Breast-Cancer-Drugs-World-Market-Prospects-2010-2025 pharma The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of breast cancer have been rising worldwide, in line with ageing populations, lifestyle/environmental factors and improvements in diagnosis. Expanding patient populations worldwide offer significant commercial and therapeutic opportunities, which our new report forecasts and discusses. Governments and other healthcare providers are investing in health education, diagnosis and treatments for this serious - but controllable - disorder. info@visiongain.com (visiongain) Wed, 09 Jun 2010 00:00:00 GMT http://www.visiongain.com/Report/481/Pharmaceutical-Anti-counterfeiting-Strategies-and-Commercial-Analysis-2010-2020 http://www.visiongain.com/Report/481/Pharmaceutical-Anti-counterfeiting-Strategies-and-Commercial-Analysis-2010-2020 pharma The pharmaceutical anti-counterfeiting market has been generating increasing revenues in recent years, with strong growth to come, as our new report explains and quantifies. Counterfeit drugs cost the pharmaceutical industry billions of dollars annually in lost revenues, with risk to patients and brands. Drug counterfeiting is increasing worldwide, with greater sophistication by counterfeiters and increased online drug purchasing. The rising prevalence of counterfeiting yields significant commercial opportunities for companies offering anti-counterfeiting solutions, as well as for their clients. Companies worldwide are investing in technologies to fight this threat to pharma stakeholders. info@visiongain.com (visiongain) Fri, 28 May 2010 00:00:00 GMT http://www.visiongain.com/Report/477/Stem-Cells-The-Hype-and-the-Hope-2010-2025 http://www.visiongain.com/Report/477/Stem-Cells-The-Hype-and-the-Hope-2010-2025 pharma In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease. info@visiongain.com (visiongain) Wed, 19 May 2010 00:00:00 GMT http://www.visiongain.com/Report/474/Biosimilars-and-Follow-On-Biologics-Global-Market-Outlook-2010-2025 http://www.visiongain.com/Report/474/Biosimilars-and-Follow-On-Biologics-Global-Market-Outlook-2010-2025 pharma In 2009, the biological (biologic) drug market generated over $125bn in revenues worldwide. There is great demand for lower-cost biological drugs. Commercial and regulatory developments will make biosimilars and follow-on biologics seize market share - our new report explains how. Many biologic patents will expire during our forecast period. There is mounting pressure from governments, insurers and patients' groups to reduce drug costs. Biologic drugs - noted as some of the most-expensive medicines - are prime targets. Developments facilitating biosimilars/follow-on biologics are gaining momentum, with commercial opportunities for the taking. The potential revenues are significant. info@visiongain.com (visiongain) Wed, 05 May 2010 00:00:00 GMT http://www.visiongain.com/Report/470/Pre-Filled-Syringes-and-Related-Systems-World-Market-Outlook-2010-2025 http://www.visiongain.com/Report/470/Pre-Filled-Syringes-and-Related-Systems-World-Market-Outlook-2010-2025 pharma The market for pre-filled syringes has achieved growth in recent years. In 2009, an estimated 2 billion pre-filled syringe units were sold and the market for that technology was estimated to be worth up to $2.5 billion. There is a trend towards pre-filled drug injection systems, away from vials/ampules, for both new and existing products. Examples are filled glass and plastic syringes, pens and low-volume auto-injection devices, including refills. That sector has shown growth of 10-15% in recent years, forming one of the fastest-expanding sectors in the pharmaceutical industry. In our new report, we predict that the pre-filled drug delivery market will grow steadily from 2010, as the number of products launched in pre-filled injectable forms increases. info@visiongain.com (visiongain) Thu, 22 Apr 2010 00:00:00 GMT http://www.visiongain.com/Report/466/Osteoporosis-Bone-Metabolism-Disorders-World-Market-2010-2025 http://www.visiongain.com/Report/466/Osteoporosis-Bone-Metabolism-Disorders-World-Market-2010-2025 pharma The bone metabolism treatments market generated pharmaceutical revenues of over $12 bn worldwide in 2009. The incidence and prevalence of bone metabolism disorders are on the rise worldwide, in line with an ageing population and improvements in diagnosis. The increasing number of older people offers significant commercial and therapeutic opportunities. The number of osteoporosis and other bone metabolism patients may exceed 400 million by 2020, reports suggest. Governments and other healthcare providers are investing in health education, diagnosis and treatments for those chronic, debilitating - but controllable - disorders, as our new report discusses. info@visiongain.com (visiongain) Fri, 09 Apr 2010 00:00:00 GMT http://www.visiongain.com/Report/461/Global-Pain-Relieving-Drug-Market-Analysis-2010-2025 http://www.visiongain.com/Report/461/Global-Pain-Relieving-Drug-Market-Analysis-2010-2025 pharma In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many conditions are increasing rapidly. Worldwide, the treatment of pain is a priority for healthcare providers, with high demand for drugs. Where is the pain relieving drug market heading - technologically and commercially - from 2010 onwards? info@visiongain.com (visiongain) Thu, 01 Apr 2010 00:00:00 GMT http://www.visiongain.com/Report/460/Inflammatory-Bowel-Disease-World-Market-2010-2025 http://www.visiongain.com/Report/460/Inflammatory-Bowel-Disease-World-Market-2010-2025 pharma Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous year. We predict that the overall market for IBD drugs will expand from 2010 onwards. Main commercial drivers will be disease prevalence, improving diagnosis and wider access to treatments. Currently, IBD is under-diagnosed, especially in developing countries. As governments and other healthcare providers address chronic illnesses like IBD, this market will expand in many countries. info@visiongain.com (visiongain) Tue, 23 Mar 2010 00:00:00 GMT http://www.visiongain.com/Report/458/Global-Vaccines-Market-2010-2025 http://www.visiongain.com/Report/458/Global-Vaccines-Market-2010-2025 pharma In 2009, the global market for vaccines achieved sales of over $10bn. Hundreds of millions of people are affected by infectious diseases that can be fought by vaccination. Despite controversy, vaccine use remains one of the greatest successes in the fight against disease - one with a long history. This market will achieve sustained growth over the next 15 years, our new study reveals. Increasingly, governments recognise the benefits of mass vaccination, with successive vaccines delivering healthcare solutions on a large scale, a trend set to continue. info@visiongain.com (visiongain) Tue, 16 Mar 2010 00:00:00 GMT http://www.visiongain.com/Report/453/World-Diabetes-Market-Analysis-2010-2025 http://www.visiongain.com/Report/453/World-Diabetes-Market-Analysis-2010-2025 pharma In 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the previous year. The incidence and prevalence of diabetes mellitus are on the rise worldwide, in line with lifestyle changes and ageing populations. In particular, the increasing prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities in developed nations and some developing countries. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing heavily in prevention and treatment of this serious - but controllable - disorder. info@visiongain.com (visiongain) Wed, 03 Mar 2010 00:00:00 GMT http://www.visiongain.com/Report/454/Global-Multiple-Sclerosis-Drug-Market-2010-2025 http://www.visiongain.com/Report/454/Global-Multiple-Sclerosis-Drug-Market-2010-2025 pharma The multiple sclerosis (MS) treatments market is one of the largest for CNS disorders, with total pharmaceutical revenues of over $8bn in 2009. Revenues for MS treatments will rise significantly from 2010 to 2025, our new study reveals. Rising disease prevalence, expanding patient populations, technological advances and widening healthcare provision for MS will drive the market upwards. In Global Multiple Sclerosis Drug Market 2010-2025 we analyse and explain trends in this market, providing sales forecasts and other core analyses that you require. Our report explains why the market will expand, revealing where the most-exciting developments will lie. info@visiongain.com (visiongain) Wed, 03 Mar 2010 00:00:00 GMT http://www.visiongain.com/Report/450/Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-and-Analysis-2010-2025 http://www.visiongain.com/Report/450/Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-and-Analysis-2010-2025 pharma The pharmaceutical wholesale and distribution sector is the vital link between pharmaceutical companies and pharmacies. Growing demand for drugs worldwide is driving that sector’s growth. However, many pressures and challenges have placed a premium on service and efficiency in pharma wholesale and distribution. What are the key issues involved? Who are the major players and how do their businesses operate? Where are the best opportunities to be found, and how could you unlock these? Our new report - Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2010-2025 - reveals where the most-exciting developments will lie from the present onwards. info@visiongain.com (visiongain) Tue, 23 Feb 2010 00:00:00 GMT http://www.visiongain.com/Report/448/Global-Anti-Obesity-Treatments-Market-2010-2025 http://www.visiongain.com/Report/448/Global-Anti-Obesity-Treatments-Market-2010-2025 pharma Prevalence of obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a "public health time-bomb". The developing world is also showing rising prevalence of obesity, now considered a serious - even life-threatening - disorder. In this report, we predict that the anti-obesity drug market will exhibit overall growth in worldwide revenues from 2010 to 2025, with new drugs entering the market during those years. Where will the best commercial prospects lie? Our new study provides the answers that you require. info@visiongain.com (visiongain) Thu, 18 Feb 2010 00:00:00 GMT http://www.visiongain.com/Report/445/Global-Antivirals-Market-2010-2025 http://www.visiongain.com/Report/445/Global-Antivirals-Market-2010-2025 pharma In 2009, the global market for antiviral drugs attained total sales of over $28bn. With hundreds of millions of people worldwide suffering from chronic or acute viral infections, there is enormous need for antiviral drugs. It is only in the past few decades that researchers have begun to find ways of combating viruses. Because viruses mutate rapidly and acquire drug-resistance, the antiviral pipeline needs to be continuously replenished with newer, better therapies, our new market study notes. info@visiongain.com (visiongain) Mon, 08 Feb 2010 00:00:00 GMT http://www.visiongain.com/Report/446/Statins-The-World-Market-2010-2025 http://www.visiongain.com/Report/446/Statins-The-World-Market-2010-2025 pharma Statins are potent cholesterol-lowering drugs, making them important in the prevention of coronary heart disease. Consequently, statins constitute one of the most important sectors of the pharmaceutical industry, with total revenues exceeding $25 billion in 2009. Our new report - Statins: The World Market 2010-2025 - provides detailed sales predictions and supporting discussions for this important pharmaceutical sector. info@visiongain.com (visiongain) Mon, 08 Feb 2010 00:00:00 GMT http://www.visiongain.com/Report/441/Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025 http://www.visiongain.com/Report/441/Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025 pharma Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. info@visiongain.com (visiongain) Mon, 25 Jan 2010 00:00:00 GMT http://www.visiongain.com/Report/442/World-Ophthalmic-Pharmaceutical-Market-2010-2025 http://www.visiongain.com/Report/442/World-Ophthalmic-Pharmaceutical-Market-2010-2025 pharma Ophthalmic drugs constitute a prominent segment of the global pharmaceutical market, with sales of over $14bn in 2009. Eye diseases are common worldwide, with expanding patient populations. The recent success of Lucentis highlighted the marked therapeutic and commercial potential of this sector. Which will be the ophthalmic blockbusters of the future? What are the most-promising R&D pipeline developments there? What are the main drivers and restraints for the market? This new report provides answers - and other essential information - to help you understand the ophthalmic pharmaceutical industry and market from 2010 onwards. info@visiongain.com (visiongain) Mon, 25 Jan 2010 00:00:00 GMT http://www.visiongain.com/Report/439/World-Smoking-Cessation-Drug-Market-2010-2025 http://www.visiongain.com/Report/439/World-Smoking-Cessation-Drug-Market-2010-2025 pharma Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public healthcare systems, as well as lowering quality of life for many people. Currently-marketed smoking-cessation products arguably lack the desired levels of efficacy in practice, with the reputation of some suffering through noted side-effects. As a result, there are significant commercial opportunities for more-efficacious and better-tolerated smoking-cessation agents, especially in prescription form. info@visiongain.com (visiongain) Wed, 13 Jan 2010 00:00:00 GMT http://www.visiongain.com/Report/436/Global-Pharmaceutical-Biotech-Market-2010-2025 http://www.visiongain.com/Report/436/Global-Pharmaceutical-Biotech-Market-2010-2025 pharma The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms. Significant R&D efforts and innovative new treatments will lead to further expansion of the pharma biotech market. This new report - Global Pharmaceutical Biotech Market 2010-2025 - explains why that market will expand, revealing where the most exciting developments will lie. info@visiongain.com (visiongain) Fri, 18 Dec 2009 00:00:00 GMT http://www.visiongain.com/Report/433/Influenza-Vaccine-Market-Outlook-2010-2020 http://www.visiongain.com/Report/433/Influenza-Vaccine-Market-Outlook-2010-2020 pharma The influenza vaccines market is one of the fastest-growing sectors of the global pharmaceutical industry, generating multi-billion dollar revenues currently. The re-emergence of influenza as a pandemic threat this decade has stimulated this market area greatly, with vaccines coming back to the fore in healthcare worldwide. Our new pharma report - Influenza Vaccine Market Outlook 2010-2020 - explains how that market area will develop and where the main commercial opportunities will lie. info@visiongain.com (visiongain) Mon, 14 Dec 2009 00:00:00 GMT http://www.visiongain.com/Report/431/The-World-Antibacterial-Treatments-Market-2010-2024 http://www.visiongain.com/Report/431/The-World-Antibacterial-Treatments-Market-2010-2024 pharma Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecasts for leading products in that sector. The global anti-infectives market generated revenues of $79bn for the 12 months to the second-quarter of 2009, of which the antibacterial market accounted for $37bn. How will this market perform from 2010 onwards? Our original forecasts and qualitative analyses will show you how the antibacterial sector will fare, pointing out the most-exciting and fast-growing areas. info@visiongain.com (visiongain) Wed, 02 Dec 2009 00:00:00 GMT http://www.visiongain.com/Report/429/The-World-Dermatological-Market-Outlook-2010-2024 http://www.visiongain.com/Report/429/The-World-Dermatological-Market-Outlook-2010-2024 pharma The dermatological drug market continues to be important and competitive globally. New treatments for skin disorders and increasing disease prevalence will lead to further expansion of that market area, we predict. There are potential gains in all the main aspects of pharma development: novel drugs, drug delivery innovation, generics and biotechnology. Our brand new report - The World Dermatological Market Outlook 2010-2024 - explains why that market will expand, revealing where the most-exciting developments will lie during our forecast period. And how you can benefit from this expansion. info@visiongain.com (visiongain) Fri, 27 Nov 2009 00:00:00 GMT http://www.visiongain.com/Report/427/The-US-Pharmaceutical-Market-2009-2024 http://www.visiongain.com/Report/427/The-US-Pharmaceutical-Market-2009-2024 pharma The United States has by far the world's largest pharmaceutical market. In the twelve months to Q2 2009, the US accounted for 41% of world pharmaceutical sales. Its vast economy, high standard of living, minimal pricing controls and strong intellectual property rights help make it the world's most dominant pharma market. The US also has one of the most stringent regulatory environments in the world. This brand new report - US Pharmaceutical Market 2009-2024 - will provide you with extensive information about the US pharma market and industry to benefit your work. info@visiongain.com (visiongain) Mon, 23 Nov 2009 00:00:00 GMT http://www.visiongain.com/Report/425/Indian-Pharmaceutical-Market-Outlook-2009-2024 http://www.visiongain.com/Report/425/Indian-Pharmaceutical-Market-Outlook-2009-2024 pharma The Indian pharmaceutical market is one of the fastest growing in the world. The rising Indian pharma market will achieve sales of close to $8 billion in 2009 and has enjoyed double-digit growth in the past five years, peaking at 25% in 2007. Will the Indian market continue to achieve high sales growth next decade? info@visiongain.com (visiongain) Wed, 11 Nov 2009 00:00:00 GMT http://www.visiongain.com/Report/422/Japanese-Pharmaceutical-Market-2009-2024 http://www.visiongain.com/Report/422/Japanese-Pharmaceutical-Market-2009-2024 pharma Japan is the second-largest pharmaceutical market in the world. As of the 12 months to Q1 2009, the Japanese pharmaceutical market accounted for nearly 10% of the world market, and generated total sales of $71.6bn. The Japanese government ensures that all citizens and workers have health insurance. Japan's healthcare expenditures have been increasing to keep up with the aging population, but the government is increasingly concerned that the expenses are unsustainable. What will happen in the Japanese pharmaceutical market next decade? info@visiongain.com (visiongain) Thu, 22 Oct 2009 00:00:00 GMT http://www.visiongain.com/Report/420/The-Global-Analgesics-Market-2009-2024 http://www.visiongain.com/Report/420/The-Global-Analgesics-Market-2009-2024 pharma There remain many unmet therapeutic needs in the treatment of pain, as well as high demand for analgesic treatments worldwide. For several types of pain, including conditions such as diabetic neuropathy and sciatica, there are currently few treatments. Furthermore, the pain sector is associated with side effects. Novel compounds that demonstrate improved safety profiles - combined with high efficacies - have the potential to gain significant market shares from 2009 onwards. info@visiongain.com (visiongain) Wed, 14 Oct 2009 00:00:00 GMT http://www.visiongain.com/Report/417/World-Neurodegenerative-Diseases-Market-2009-2024 http://www.visiongain.com/Report/417/World-Neurodegenerative-Diseases-Market-2009-2024 pharma The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards. info@visiongain.com (visiongain) Fri, 18 Sep 2009 00:00:00 GMT http://www.visiongain.com/Report/412/Chinese-Pharmaceutical-Market-Outlook-2009-2024 http://www.visiongain.com/Report/412/Chinese-Pharmaceutical-Market-Outlook-2009-2024 pharma In November 2008, China announced a major economic stimulus package, including $124bn to be spent on healthcare. These changes will have a major impact on the Chinese pharmaceutical landscape over the next 15 years, as the stimulus increases the number of clinics in rural areas, dissociates pharmacies from hospitals and promises healthcare coverage to 100% of the population by 2020. This report analyses prospects for the pharma market and industry sector in China. info@visiongain.com (visiongain) Thu, 27 Aug 2009 00:00:00 GMT http://www.visiongain.com/Report/411/World-Generics-Market-2009-2024 http://www.visiongain.com/Report/411/World-Generics-Market-2009-2024 pharma The generic pharmaceuticals sector has been expanding strongly in recent years as the need for cheaper medicines worldwide has increased. The next five years from 2009 will see more leading drugs going off patent, thus increasing opportunities for generics producers. Regulations favouring generic products give cause for optimism in the generics sector, while still leaving scope for novel branded drugs. We predict that total revenues in the generics market will continue to increase in the years ahead. info@visiongain.com (visiongain) Wed, 26 Aug 2009 00:00:00 GMT http://www.visiongain.com/Report/408/Monoclonal-Antibody-Therapeutics-2009-2024 http://www.visiongain.com/Report/408/Monoclonal-Antibody-Therapeutics-2009-2024 pharma Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. We expect significant opportunities for further commercial growth from 2009 to 2024, as shown in our new report. New technologies will be an important growth driver. Intensive R&D activity is producing an exciting antibody pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. info@visiongain.com (visiongain) Thu, 06 Aug 2009 00:00:00 GMT http://www.visiongain.com/Report/403/Clinical-Trials-World-Market-2009-2024 http://www.visiongain.com/Report/403/Clinical-Trials-World-Market-2009-2024 pharma The market for clinical trials has been expanding rapidly in recent years, with impressive revenue growth and important trends. One regional market expanded by 65% in 2008. From the perspectives of various pharma stakeholders, the expanding clinical research market represents opportunities for revenue growth and cost savings. Our latest report considers perspectives of pharma companies and CROs in particular. We comprehensively analyse the market's strengths, weaknesses and revenue trends from 2009 to 2024. info@visiongain.com (visiongain) Wed, 22 Jul 2009 00:00:00 GMT http://www.visiongain.com/Report/401/World-AMD-and-Diabetic-Retinopathy-Pharmaceutical-Market-2009-2024 http://www.visiongain.com/Report/401/World-AMD-and-Diabetic-Retinopathy-Pharmaceutical-Market-2009-2024 pharma The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment of wet AMD. info@visiongain.com (visiongain) Wed, 08 Jul 2009 00:00:00 GMT http://www.visiongain.com/Report/399/Global-Cardiovascular-Drugs-Market-2009-2024 http://www.visiongain.com/Report/399/Global-Cardiovascular-Drugs-Market-2009-2024 pharma Cardiovascular disorders are leading causes of death worldwide. Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets. info@visiongain.com (visiongain) Tue, 30 Jun 2009 00:00:00 GMT http://www.visiongain.com/Report/398/World-Respiratory-Disorders-Market-2009-2024 http://www.visiongain.com/Report/398/World-Respiratory-Disorders-Market-2009-2024 pharma Respiratory disorder therapies form an important and competitive part of the pharmaceutical market worldwide. There are wide ranges of drugs and therapeutic needs, both acute and chronic. Revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. Our new pharma report will give you the analytical information that you need to understand current trends and likely future events in this market area. info@visiongain.com (visiongain) Tue, 23 Jun 2009 00:00:00 GMT http://www.visiongain.com/Report/396/World-Sleep-Disorders-Market-Analysis-2009-2024 http://www.visiongain.com/Report/396/World-Sleep-Disorders-Market-Analysis-2009-2024 pharma Sleep disorders affect hundreds of millions of people worldwide. It is a multi-billion dollar market for drug-based treatments with continuing potential for growth. This new report - World Sleep Disorders Market Analysis 2009-2024 - explains the commercial prospects for drugs to treat sleep disorders, an important, changing pharma market. The principal disorders are insomnia, narcolepsy, sleep apnea and restless leg syndrome, but there other potentially profitable market segments. Overall, sleep disorders are highly prevalent. info@visiongain.com (visiongain) Thu, 18 Jun 2009 00:00:00 GMT http://www.visiongain.com/Report/392/In-Vitro-Diagnostics-Market-Analysis-2009-2024 http://www.visiongain.com/Report/392/In-Vitro-Diagnostics-Market-Analysis-2009-2024 pharma In vitro diagnostics constitute an important, growing healthcare industry and market, one that is increasingly biotechnological and closely aligned with pharma. In vitro diagnostic (IVD) tests provide essential information about physiological states, aiding diagnoses and choice of treatments. IVD's usefulness in drug development - especially via biomarkers - constitutes a major advance, and an expanding market opportunity. Our new report - In Vitro Diagnostics: Market Analysis 2009-2024 - analyses the global IVD market comprehensively. info@visiongain.com (visiongain) Fri, 29 May 2009 00:00:00 GMT http://www.visiongain.com/Report/393/The-Global-OTC-Pharmaceutical-Market-2009-2024 http://www.visiongain.com/Report/393/The-Global-OTC-Pharmaceutical-Market-2009-2024 pharma General economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. In this new report visiongain notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. Our forecasts reveal that the OTC pharma market will grow significantly next decade. This report explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty, visiongain asserts. info@visiongain.com (visiongain) Thu, 21 May 2009 00:00:00 GMT http://www.visiongain.com/Report/394/Monoclonal-Antibodies-in-Cancer-Therapy-2009-2024 http://www.visiongain.com/Report/394/Monoclonal-Antibodies-in-Cancer-Therapy-2009-2024 pharma Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both mature and emerging geographical markets. info@visiongain.com (visiongain) Thu, 07 May 2009 00:00:00 GMT http://www.visiongain.com/Report/395/Pharmacovigilance-Report-and-Analysis-2009-Present-Challenges-and-Future-Goals http://www.visiongain.com/Report/395/Pharmacovigilance-Report-and-Analysis-2009-Present-Challenges-and-Future-Goals pharma Pharmacovigilance has been expanding in recent years, as companies are required to monitor drug safety post launch. Drug safety issues, such as those raised by Vioxx earlier this decade, have led to increased risk-averseness by regulators, with greater post-marketing assessment of drugs. Many regulatory agencies require detailed pharmacovigilance, with companies bearing extra costs, our new report also observes. info@visiongain.com (visiongain) Tue, 21 Apr 2009 00:00:00 GMT http://www.visiongain.com/Report/381/Biosimilars-and-Follow-On-Biologics-Report-The-Global-Outlook-2009-2024 http://www.visiongain.com/Report/381/Biosimilars-and-Follow-On-Biologics-Report-The-Global-Outlook-2009-2024 pharma This report predicts how the biosimilar market will evolve from 2009 to 2024. We indentify and discuss the biosimilar drugs and manufacturers that will achieve commercial success during the coming fifteen years. info@visiongain.com (visiongain) Thu, 09 Apr 2009 00:00:00 GMT http://www.visiongain.com/Report/376/Stem-Cells-The-Hype-Hope-World-Analysis-2009-2024 http://www.visiongain.com/Report/376/Stem-Cells-The-Hype-Hope-World-Analysis-2009-2024 pharma Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials. info@visiongain.com (visiongain) Mon, 23 Mar 2009 00:00:00 GMT http://www.visiongain.com/Report/374/The-Global-Multiple-Sclerosis-Market-2009-2024 http://www.visiongain.com/Report/374/The-Global-Multiple-Sclerosis-Market-2009-2024 pharma The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies. info@visiongain.com (visiongain) Thu, 19 Mar 2009 00:00:00 GMT http://www.visiongain.com/Report/369/Statins-The-World-Market-2009-2024 http://www.visiongain.com/Report/369/Statins-The-World-Market-2009-2024 pharma The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently, those drugs are one of the most widely-prescribed and most lucrative sectors of the pharmaceutical industry, with total revenues exceeding $26 billion in 2008. info@visiongain.com (visiongain) Tue, 03 Mar 2009 00:00:00 GMT http://www.visiongain.com/Report/366/Inflammatory-Bowel-Diseases-World-Market-Report-2009-2024 http://www.visiongain.com/Report/366/Inflammatory-Bowel-Diseases-World-Market-Report-2009-2024 pharma This brand new in-depth market analysis examines the current and future prospects of the inflammatory bowel diseases (IBD) market. The world market for intestinal anti-inflammatories was worth over $2400 million in 2008, and had grown at 9% over the previous year. info@visiongain.com (visiongain) Mon, 23 Feb 2009 00:00:00 GMT http://www.visiongain.com/Report/367/Anti-Obesity-Treatments-Report-Analysis-Forecasts-2009-2024 http://www.visiongain.com/Report/367/Anti-Obesity-Treatments-Report-Analysis-Forecasts-2009-2024 pharma Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 - explains those trends in commercial terms. info@visiongain.com (visiongain) Mon, 23 Feb 2009 00:00:00 GMT http://www.visiongain.com/Report/364/World-Diabetes-Market-Analysis-2009-2023 http://www.visiongain.com/Report/364/World-Diabetes-Market-Analysis-2009-2023 pharma Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder. info@visiongain.com (visiongain) Tue, 10 Feb 2009 00:00:00 GMT http://www.visiongain.com/Report/361/Smoking-Cessation-Report-2009-2024 http://www.visiongain.com/Report/361/Smoking-Cessation-Report-2009-2024 pharma Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms. info@visiongain.com (visiongain) Tue, 03 Feb 2009 00:00:00 GMT http://www.visiongain.com/Report/358/Ophthalmic-Pharmaceuticals-Market-Analysis-Forecasts-and-Dynamics-2009-2023 http://www.visiongain.com/Report/358/Ophthalmic-Pharmaceuticals-Market-Analysis-Forecasts-and-Dynamics-2009-2023 pharma The global market for ophthalmic pharmaceuticals is a large and profitable segment of the healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs and highlighted the lucrative commercial rewards on offer in this sector. Which will be the blockbusters of the future? info@visiongain.com (visiongain) Thu, 15 Jan 2009 00:00:00 GMT http://www.visiongain.com/Report/357/The-World-Dermatological-Market-Outlook-2009-2023 http://www.visiongain.com/Report/357/The-World-Dermatological-Market-Outlook-2009-2023 pharma This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. info@visiongain.com (visiongain) Thu, 08 Jan 2009 00:00:00 GMT http://www.visiongain.com/Report/355/Top-10-Biotech-Companies-Market-Outlook-2008-2023 http://www.visiongain.com/Report/355/Top-10-Biotech-Companies-Market-Outlook-2008-2023 pharma The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970's. info@visiongain.com (visiongain) Thu, 04 Dec 2008 00:00:00 GMT http://www.visiongain.com/Report/353/World-Generics-Market-2008-2013 http://www.visiongain.com/Report/353/World-Generics-Market-2008-2013 pharma The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market. info@visiongain.com (visiongain) Mon, 24 Nov 2008 00:00:00 GMT http://www.visiongain.com/Report/351/The-Global-Pain-Market-2008-2023 http://www.visiongain.com/Report/351/The-Global-Pain-Market-2008-2023 pharma The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you. info@visiongain.com (visiongain) Thu, 13 Nov 2008 00:00:00 GMT http://www.visiongain.com/Report/346/The-Global-Anti-Addiction-Market-2008-2023 http://www.visiongain.com/Report/346/The-Global-Anti-Addiction-Market-2008-2023 pharma The global addiction market is significantly undervalued. The world's population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. info@visiongain.com (visiongain) Wed, 05 Nov 2008 00:00:00 GMT http://www.visiongain.com/Report/344/World-Gastrointestinal-Disorders-Market-2008-2023 http://www.visiongain.com/Report/344/World-Gastrointestinal-Disorders-Market-2008-2023 pharma The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. However. the market is now mature, with well-established treatments now nearing the end of their patent life. So can you and your company continue to benefit from this market? info@visiongain.com (visiongain) Thu, 30 Oct 2008 00:00:00 GMT http://www.visiongain.com/Report/342/The-Japanese-Pharmaceutical-Market-2008-2023 http://www.visiongain.com/Report/342/The-Japanese-Pharmaceutical-Market-2008-2023 pharma Last year, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5bn. However, Japan’s market has experienced growth at a much lower rate than the other major pharmaceutical markets. It is at a key stage in its development. You need to take notice of these changes. info@visiongain.com (visiongain) Fri, 10 Oct 2008 00:00:00 GMT http://www.visiongain.com/Report/340/Women's-Reproductive-Disorders-Therapeutics-2008-2018 http://www.visiongain.com/Report/340/Women's-Reproductive-Disorders-Therapeutics-2008-2018 pharma This visiongain report provides a detailed analysis of the market for women's reproductive health pharmaceutical products. The report discusses current and future products and market climates for the following areas: - Hormonal contraceptive use - Use of hormone replacement therapy (HRT) for menopause - Infertility therapeutics. info@visiongain.com (visiongain) Tue, 30 Sep 2008 00:00:00 GMT http://www.visiongain.com/Report/338/Global-Antivirals-Market-Analysis-Forecasts-2008-2023 http://www.visiongain.com/Report/338/Global-Antivirals-Market-Analysis-Forecasts-2008-2023 pharma Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market. Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market. info@visiongain.com (visiongain) Wed, 10 Sep 2008 00:00:00 GMT http://www.visiongain.com/Report/336/The-Global-Vaccines-Market-2008-2023 http://www.visiongain.com/Report/336/The-Global-Vaccines-Market-2008-2023 pharma The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer. info@visiongain.com (visiongain) Mon, 01 Sep 2008 00:00:00 GMT http://www.visiongain.com/Report/333/Global-Biotech-Market-Analysis-and-Forecasts-2008-2023 http://www.visiongain.com/Report/333/Global-Biotech-Market-Analysis-and-Forecasts-2008-2023 pharma The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970s. info@visiongain.com (visiongain) Tue, 26 Aug 2008 00:00:00 GMT http://www.visiongain.com/Report/330/Contract-Pharma-2008-2023 http://www.visiongain.com/Report/330/Contract-Pharma-2008-2023 pharma The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing organisations (CMOs) make them increasingly essential to you and your organisation. info@visiongain.com (visiongain) Fri, 15 Aug 2008 00:00:00 GMT http://www.visiongain.com/Report/331/Osteoporosis-Bone-Metabolism-Disorders-Market-2008-2023-Management-Report http://www.visiongain.com/Report/331/Osteoporosis-Bone-Metabolism-Disorders-Market-2008-2023-Management-Report pharma In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured? info@visiongain.com (visiongain) Fri, 15 Aug 2008 00:00:00 GMT http://www.visiongain.com/Report/326/Pfizer-Market-Outlook-for-a-Global-Leader-2008-2013 http://www.visiongain.com/Report/326/Pfizer-Market-Outlook-for-a-Global-Leader-2008-2013 pharma Pfizer is the world's largest and most profitable pharmaceutical company. Its pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. info@visiongain.com (visiongain) Fri, 08 Aug 2008 00:00:00 GMT http://www.visiongain.com/Report/319/Therapeutic-Monoclonal-Antibodies-Report-2008-2023 http://www.visiongain.com/Report/319/Therapeutic-Monoclonal-Antibodies-Report-2008-2023 pharma This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a double-digit rate. info@visiongain.com (visiongain) Fri, 25 Jul 2008 00:00:00 GMT http://www.visiongain.com/Report/315/Global-Clinical-Trial-Business-Report-Analysis-2008-2018 http://www.visiongain.com/Report/315/Global-Clinical-Trial-Business-Report-Analysis-2008-2018 pharma The global clinical trials business is worth an estimated $50bn in 2008, with a growth of rate of 10%. The market will show considerable growth in the future, as this visiongain report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the nature of clinical trials has changed considerably. info@visiongain.com (visiongain) Thu, 10 Jul 2008 00:00:00 GMT http://www.visiongain.com/Report/323/Oncology-Market-Leaders-Analyses-and-Outlook-Market-Report-2008-2023 http://www.visiongain.com/Report/323/Oncology-Market-Leaders-Analyses-and-Outlook-Market-Report-2008-2023 pharma The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said. info@visiongain.com (visiongain) Thu, 10 Jul 2008 00:00:00 GMT http://www.visiongain.com/Report/303/In-Vitro-Diagnostics-Market-Report-Analysis-2008-2023 http://www.visiongain.com/Report/303/In-Vitro-Diagnostics-Market-Report-Analysis-2008-2023 pharma Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics - especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. info@visiongain.com (visiongain) Wed, 25 Jun 2008 00:00:00 GMT http://www.visiongain.com/Report/308/Amgen-The-Biotech-Leader-Market-Analyses-and-Outlook-2008-2023 http://www.visiongain.com/Report/308/Amgen-The-Biotech-Leader-Market-Analyses-and-Outlook-2008-2023 pharma In 2007, Amgen Inc - the world's largest biotechnology company - achieved total sales of $14.7bn, despite a turbulent year marked by regulatory, pricing and reimbursement issues. Amgen has now firmly established itself as a Top-20 international pharmaceutical company. According to sales data for 2007, Amgen is also ranked as the 11th largest pharmaceutical company worldwide based on total sales value. This is a remarkable achievment for a biotechnology company founded in 1980. info@visiongain.com (visiongain) Thu, 19 Jun 2008 00:00:00 GMT http://www.visiongain.com/Report/322/The-World-OTC-Pharmaceutical-Market-Analysis-Forecasts-2008-2023 http://www.visiongain.com/Report/322/The-World-OTC-Pharmaceutical-Market-Analysis-Forecasts-2008-2023 pharma Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. info@visiongain.com (visiongain) Wed, 18 Jun 2008 00:00:00 GMT http://www.visiongain.com/Report/320/The-Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-Analysis-2008 http://www.visiongain.com/Report/320/The-Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-Analysis-2008 pharma The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. info@visiongain.com (visiongain) Mon, 02 Jun 2008 00:00:00 GMT http://www.visiongain.com/Report/269/The-Indian-Pharmaceutical-Market http://www.visiongain.com/Report/269/The-Indian-Pharmaceutical-Market pharma The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry's leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. info@visiongain.com (visiongain) Fri, 16 May 2008 00:00:00 GMT http://www.visiongain.com/Report/272/Lipitor-Market-analysis-and-forecasts-Report http://www.visiongain.com/Report/272/Lipitor-Market-analysis-and-forecasts-Report pharma In 2006, Pfizer's Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. info@visiongain.com (visiongain) Tue, 06 May 2008 00:00:00 GMT http://www.visiongain.com/Report/306/Chinese-Pharmaceutical-Outlook-2008-2023 http://www.visiongain.com/Report/306/Chinese-Pharmaceutical-Outlook-2008-2023 pharma This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains. info@visiongain.com (visiongain) Wed, 16 Apr 2008 00:00:00 GMT http://www.visiongain.com/Report/352/Pharmaceutical-Control-of-Blood-Diseases-Market-Analysis-Forecasts-Report-2008 http://www.visiongain.com/Report/352/Pharmaceutical-Control-of-Blood-Diseases-Market-Analysis-Forecasts-Report-2008 pharma In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. info@visiongain.com (visiongain) Mon, 14 Apr 2008 00:00:00 GMT http://www.visiongain.com/Report/274/Sleep-Disorders-Market-Analysis-2008-2018 http://www.visiongain.com/Report/274/Sleep-Disorders-Market-Analysis-2008-2018 pharma The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness physicians better comprehension of the significance of this disease and the positive role that a sleep medication prescription plays. info@visiongain.com (visiongain) Tue, 25 Mar 2008 00:00:00 GMT http://www.visiongain.com/Report/275/The-Antibacterial-Drug-Market-Analysis-2008-2013 http://www.visiongain.com/Report/275/The-Antibacterial-Drug-Market-Analysis-2008-2013 pharma This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. info@visiongain.com (visiongain) Wed, 19 Mar 2008 00:00:00 GMT http://www.visiongain.com/Report/276/Generic-League http://www.visiongain.com/Report/276/Generic-League pharma The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality. info@visiongain.com (visiongain) Wed, 27 Feb 2008 00:00:00 GMT http://www.visiongain.com/Report/278/The-Antipsychotics-Market-Insight-Analysis-2008 http://www.visiongain.com/Report/278/The-Antipsychotics-Market-Insight-Analysis-2008 pharma The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? info@visiongain.com (visiongain) Tue, 19 Feb 2008 00:00:00 GMT http://www.visiongain.com/Report/280/Respiratory-Market-Insight-2008 http://www.visiongain.com/Report/280/Respiratory-Market-Insight-2008 pharma This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year will see it reach its peak? info@visiongain.com (visiongain) Mon, 11 Feb 2008 00:00:00 GMT http://www.visiongain.com/Report/282/Live-Licensing-In-life-testing-R-D-Processes-and-Regulation-for-New-Drugs-2008-2020 http://www.visiongain.com/Report/282/Live-Licensing-In-life-testing-R-D-Processes-and-Regulation-for-New-Drugs-2008-2020 pharma Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as "in-life testing" or "live-licensing". Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. info@visiongain.com (visiongain) Thu, 17 Jan 2008 00:00:00 GMT http://www.visiongain.com/Report/283/Parkinson's-Disease-Market-analysis-and-forecasts-2008-2012-2017-2022 http://www.visiongain.com/Report/283/Parkinson's-Disease-Market-analysis-and-forecasts-2008-2012-2017-2022 pharma Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease. info@visiongain.com (visiongain) Tue, 08 Jan 2008 00:00:00 GMT http://www.visiongain.com/Report/285/Erectile-Dysfunction-Market-Assessment-Analysis-2007-2022 http://www.visiongain.com/Report/285/Erectile-Dysfunction-Market-Assessment-Analysis-2007-2022 pharma The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market. Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. info@visiongain.com (visiongain) Sat, 15 Dec 2007 00:00:00 GMT http://www.visiongain.com/Report/286/The-World-Dermatological-Market-Analysis-Forecasts-2007-2022 http://www.visiongain.com/Report/286/The-World-Dermatological-Market-Analysis-Forecasts-2007-2022 pharma Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness increases in Western countries, botulinum toxin and other cosmetic treatments become more and more popular. info@visiongain.com (visiongain) Mon, 26 Nov 2007 00:00:00 GMT http://www.visiongain.com/Report/288/The-Anti-Migraine-Market-2007-2022 http://www.visiongain.com/Report/288/The-Anti-Migraine-Market-2007-2022 pharma Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. info@visiongain.com (visiongain) Tue, 13 Nov 2007 00:00:00 GMT http://www.visiongain.com/Report/291/The-Global-Non-Opioid-Market-in-Pain-Management-2007-2022 http://www.visiongain.com/Report/291/The-Global-Non-Opioid-Market-in-Pain-Management-2007-2022 pharma Visiongain believe that the market for non-opioid drugs is the fastest growing segments in pain management with a CAGR of 8.12% for the period 2006-2012. The brand new report entitled “The Global Non-Opioid Market in Pain Management" has highlighted a number of innovative pipeline developments that are set to shape the industry over the medium term. info@visiongain.com (visiongain) Wed, 24 Oct 2007 00:00:00 GMT http://www.visiongain.com/Report/292/Blockbuster-Drugs-Create-Develop-and-Market-a-Billion-Dollar-Drug-2007-2012 http://www.visiongain.com/Report/292/Blockbuster-Drugs-Create-Develop-and-Market-a-Billion-Dollar-Drug-2007-2012 pharma This unique in-depth management report examines the future prospects for blockbuster drugs from 2007-2012. It delivers direct to you future sales forecasts for leading pharmaceutical blockbuster products. In 2006, there were over a hundred of those high revenue generating drugs in the global market. This detailed report also highlights pipeline developments, potential blockbusters on the market and important contemporary issues, especially commercial drivers and restraints. info@visiongain.com (visiongain) Tue, 23 Oct 2007 00:00:00 GMT http://www.visiongain.com/Report/293/Alzheimer's-Disease-Market-analysis-and-forecasts-2007-2012-2017-2022 http://www.visiongain.com/Report/293/Alzheimer's-Disease-Market-analysis-and-forecasts-2007-2012-2017-2022 pharma Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped. info@visiongain.com (visiongain) Mon, 15 Oct 2007 00:00:00 GMT http://www.visiongain.com/Report/295/The-World-Diabetes-Market-2007-2025-A-Key-Pharmaceutical-Market-of-the-Future http://www.visiongain.com/Report/295/The-World-Diabetes-Market-2007-2025-A-Key-Pharmaceutical-Market-of-the-Future pharma Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. info@visiongain.com (visiongain) Wed, 03 Oct 2007 00:00:00 GMT http://www.visiongain.com/Report/296/The-Global-Pain-Pharmaceutical-Market-Analysis-Forecasts-2007-2022 http://www.visiongain.com/Report/296/The-Global-Pain-Pharmaceutical-Market-Analysis-Forecasts-2007-2022 pharma The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012. Visiongain's latest report, “The Global Pain Pharmaceutical Market 2007-2022“, explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. info@visiongain.com (visiongain) Thu, 27 Sep 2007 00:00:00 GMT http://www.visiongain.com/Report/298/The-World-Hypertension-Market-2007-2023 http://www.visiongain.com/Report/298/The-World-Hypertension-Market-2007-2023 pharma The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. info@visiongain.com (visiongain) Mon, 17 Sep 2007 00:00:00 GMT http://www.visiongain.com/Report/300/Multiple-Sclerosis-Market-Analysis-Forecasts-Report-2007-2022 http://www.visiongain.com/Report/300/Multiple-Sclerosis-Market-Analysis-Forecasts-Report-2007-2022 pharma The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7.6 billion by 2020, the prevalence and onset of MS in children and particularly adults is expected to rise exponentially. info@visiongain.com (visiongain) Thu, 30 Aug 2007 00:00:00 GMT http://www.visiongain.com/Report/264/Lou-Gehrig-Disease-Report-Is-there-a-link-between-Lipitor-and-ALS http://www.visiongain.com/Report/264/Lou-Gehrig-Disease-Report-Is-there-a-link-between-Lipitor-and-ALS pharma Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of motor nerve cell in the brain (upper motor neurons) and spinal cord (lower motor). info@visiongain.com (visiongain) Thu, 02 Aug 2007 00:00:00 GMT http://www.visiongain.com/Report/262/Top-Companies-and-Products-in-the-RNA-DNA-Therapy-Products-Market-Forecasts-The-challenge-of-turning-technology-into-therapy http://www.visiongain.com/Report/262/Top-Companies-and-Products-in-the-RNA-DNA-Therapy-Products-Market-Forecasts-The-challenge-of-turning-technology-into-therapy pharma Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. info@visiongain.com (visiongain) Mon, 23 Jul 2007 00:00:00 GMT http://www.visiongain.com/Report/260/Anti-Obesity-Treatments-2007-2012-A-blockbuster-target-market http://www.visiongain.com/Report/260/Anti-Obesity-Treatments-2007-2012-A-blockbuster-target-market pharma By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. info@visiongain.com (visiongain) Fri, 13 Jul 2007 00:00:00 GMT http://www.visiongain.com/Report/258/Global-Smoking-Cessation-Market-Analysis-Forecasts-Preparing-for-the-first-blockbuster http://www.visiongain.com/Report/258/Global-Smoking-Cessation-Market-Analysis-Forecasts-Preparing-for-the-first-blockbuster pharma Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies? info@visiongain.com (visiongain) Wed, 04 Jul 2007 00:00:00 GMT http://www.visiongain.com/Report/256/Parallel-Trade-US-Lawmakers-allow-imported-prescriptions-drugs http://www.visiongain.com/Report/256/Parallel-Trade-US-Lawmakers-allow-imported-prescriptions-drugs pharma Parallel trade is on the verge of breaking its confines of the EU and diffusing into other global markets. This global practice is far from simple, and the loopholes that have made it possible refuse to close. Whether you think parallel trade is a benefit or a cost, the reality is that it is affecting the whole pharma industry on a wide scale. It started out a North-South divide but even this is changing. The European Commission and other trade regulation bodies won't protect the pharma companies pricing structures. info@visiongain.com (visiongain) Thu, 21 Jun 2007 00:00:00 GMT http://www.visiongain.com/Report/253/Rimonabant-The-first-of-the-Cannabinoid-blockbusters http://www.visiongain.com/Report/253/Rimonabant-The-first-of-the-Cannabinoid-blockbusters pharma Marinol®, Cesamet®, Sativex® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the drugs are changing. This increased acceptance will lead to greater market penetration, and the importance of the area will be seen with the first cannabinoid reaching blockbuster status before the end of the decade. info@visiongain.com (visiongain) Fri, 15 Jun 2007 00:00:00 GMT http://www.visiongain.com/Report/254/Neurodegenerative-Disease-Drug-Market-Analysis-and-Forecasts-2007 http://www.visiongain.com/Report/254/Neurodegenerative-Disease-Drug-Market-Analysis-and-Forecasts-2007 pharma With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries. info@visiongain.com (visiongain) Fri, 15 Jun 2007 00:00:00 GMT http://www.visiongain.com/Report/251/Gastrointestinal-Disorders-Market-Intelligence-to-2012 http://www.visiongain.com/Report/251/Gastrointestinal-Disorders-Market-Intelligence-to-2012 pharma Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise. info@visiongain.com (visiongain) Fri, 25 May 2007 00:00:00 GMT http://www.visiongain.com/Report/250/Teva-Pharmaceutical-Industries-Market-Forecasts-Analysis-2007-2012 http://www.visiongain.com/Report/250/Teva-Pharmaceutical-Industries-Market-Forecasts-Analysis-2007-2012 pharma In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. info@visiongain.com (visiongain) Thu, 17 May 2007 00:00:00 GMT http://www.visiongain.com/Report/247/Global-Ophthalmic-Market-Analysis-Forecasts-to-2012 http://www.visiongain.com/Report/247/Global-Ophthalmic-Market-Analysis-Forecasts-to-2012 pharma Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints. info@visiongain.com (visiongain) Mon, 30 Apr 2007 00:00:00 GMT http://www.visiongain.com/Report/245/Dr-Reddy's-Market-Outlook-Forecasts-and-Analysis-to-2012 http://www.visiongain.com/Report/245/Dr-Reddy's-Market-Outlook-Forecasts-and-Analysis-to-2012 pharma Founded by Indian Scientist Dr Anji Reddy in 1984, the company has developed into a fast-growing international corporation, with headquarters in Hyderabad, Andhra Pradesh, India. During the fiscal year 2006, Dr. Reddy's was the third-largest Indian pharmaceutical company, with net revenue of $546m. info@visiongain.com (visiongain) Wed, 11 Apr 2007 00:00:00 GMT http://www.visiongain.com/Report/243/GSK's-Cervarix-a-future-blockbuster-of-2007 http://www.visiongain.com/Report/243/GSK's-Cervarix-a-future-blockbuster-of-2007 pharma The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, GSK's Cervarix, intended for the prevention of infection and lesions from the two cancer-causing types of HPVs holds great potential. info@visiongain.com (visiongain) Thu, 22 Mar 2007 00:00:00 GMT http://www.visiongain.com/Report/244/Cannabinoid-Market-Forecasts-Analysis-to-2012 http://www.visiongain.com/Report/244/Cannabinoid-Market-Forecasts-Analysis-to-2012 pharma With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty. info@visiongain.com (visiongain) Thu, 22 Mar 2007 00:00:00 GMT http://www.visiongain.com/Report/242/AMD-Market-Outlook-to-2012 http://www.visiongain.com/Report/242/AMD-Market-Outlook-to-2012 pharma AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure. Wet AMD drug sales will soon see the first blockbuster. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and Lucentis from Genentech have seen it sales reduced. These drugs are referred to in the press as “miracle drugs" - saving sight for millions. info@visiongain.com (visiongain) Fri, 16 Mar 2007 00:00:00 GMT http://www.visiongain.com/Report/238/The-Global-Rheumatoid-Arthritis-Market-Forecasts-to-2012 http://www.visiongain.com/Report/238/The-Global-Rheumatoid-Arthritis-Market-Forecasts-to-2012 pharma In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide. info@visiongain.com (visiongain) Fri, 09 Mar 2007 00:00:00 GMT http://www.visiongain.com/Report/235/Tissue-Engineering-Stem-Cell-Technology-Report-2007 http://www.visiongain.com/Report/235/Tissue-Engineering-Stem-Cell-Technology-Report-2007 pharma The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology. info@visiongain.com (visiongain) Wed, 28 Feb 2007 00:00:00 GMT http://www.visiongain.com/Report/234/Novartis-Market-Outlook-Forecasts-and-Analysis-to-2012 http://www.visiongain.com/Report/234/Novartis-Market-Outlook-Forecasts-and-Analysis-to-2012 pharma With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide. info@visiongain.com (visiongain) Tue, 27 Feb 2007 00:00:00 GMT http://www.visiongain.com/Report/232/Biotech-Drug-Delivery-Systems-Key-Company-Intelligence-Market-Outlook-to-2012 http://www.visiongain.com/Report/232/Biotech-Drug-Delivery-Systems-Key-Company-Intelligence-Market-Outlook-to-2012 pharma The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs. info@visiongain.com (visiongain) Mon, 19 Feb 2007 00:00:00 GMT http://www.visiongain.com/Report/230/The-Autoimmune-Inflammatory-Bowel-Disease-Market-Outlook-to-2012 http://www.visiongain.com/Report/230/The-Autoimmune-Inflammatory-Bowel-Disease-Market-Outlook-to-2012 pharma 'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. info@visiongain.com (visiongain) Tue, 06 Feb 2007 00:00:00 GMT http://www.visiongain.com/Report/229/Theranostics-Report-2007-2012 http://www.visiongain.com/Report/229/Theranostics-Report-2007-2012 pharma Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it alot easier for you and your company... info@visiongain.com (visiongain) Wed, 31 Jan 2007 00:00:00 GMT http://www.visiongain.com/Report/228/Stem-Cells-The-hype-and-the-hope-Business-opportunities-and-forecasts http://www.visiongain.com/Report/228/Stem-Cells-The-hype-and-the-hope-Business-opportunities-and-forecasts pharma The news has been full of industry developments and financial investments in stem cell research in recent weeks. Your company must be aware of the latest developments immediately... info@visiongain.com (visiongain) Tue, 23 Jan 2007 00:00:00 GMT http://www.visiongain.com/Report/227/World-market-for-cancer-vaccines-2007-2012 http://www.visiongain.com/Report/227/World-market-for-cancer-vaccines-2007-2012 pharma Previously the cancer vaccine market has consisted of HBV (hepatitis B virus) vaccines to prevent liver cancer. 2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Another HPV vaccine, Cervarix, is due to be launched in 2007... info@visiongain.com (visiongain) Wed, 17 Jan 2007 00:00:00 GMT http://www.visiongain.com/Report/222/Therapeutic-Monoclonal-Antibodies-2006-2011-Maximising-the-Growth-Potential-of-a-Stocked-Pipeline http://www.visiongain.com/Report/222/Therapeutic-Monoclonal-Antibodies-2006-2011-Maximising-the-Growth-Potential-of-a-Stocked-Pipeline pharma While the pharmaceutical as a whole is suffering from single digit growth, thin uninspiring pipelines and pressure from an ever-aggressive generics industry - not so for monoclonal antibody therapies. The market for monoclonal antibody treatments is one of the most exciting segments of the pharmaceutical industry today... info@visiongain.com (visiongain) Thu, 07 Dec 2006 00:00:00 GMT http://www.visiongain.com/Report/221/Central-and-Eastern-European-(CEE)-Developing-Markets-for-Pharmaceuticals-2006-2011 http://www.visiongain.com/Report/221/Central-and-Eastern-European-(CEE)-Developing-Markets-for-Pharmaceuticals-2006-2011 pharma Central and Eastern European Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors... info@visiongain.com (visiongain) Thu, 23 Nov 2006 00:00:00 GMT http://www.visiongain.com/Report/220/Latin-American-Developing-Markets-for-Pharmaceuticals-2006-2011 http://www.visiongain.com/Report/220/Latin-American-Developing-Markets-for-Pharmaceuticals-2006-2011 pharma The purpose of visiongain's Developing Markets Series is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe... info@visiongain.com (visiongain) Thu, 16 Nov 2006 00:00:00 GMT http://www.visiongain.com/Report/218/Asian-Developing-Markets-for-Pharmaceuticals-2006-2011 http://www.visiongain.com/Report/218/Asian-Developing-Markets-for-Pharmaceuticals-2006-2011 pharma Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them? info@visiongain.com (visiongain) Thu, 09 Nov 2006 00:00:00 GMT http://www.visiongain.com/Report/217/Bioinformatics-Report-The-forecasts-and-future-of-the-market-2006-2011 http://www.visiongain.com/Report/217/Bioinformatics-Report-The-forecasts-and-future-of-the-market-2006-2011 pharma This report delivers answers on how you can benefit from the commercial prospects of bioinformatics, now. The ultimate goal of bioinformatics is to uncover the wealth of biological information hidden in the mass of data, to obtain a clearer insight into the fundamental biology of organisms... info@visiongain.com (visiongain) Thu, 26 Oct 2006 00:00:00 GMT http://www.visiongain.com/Report/216/Anti-addiction-Therapies-2006-2011-The-Pharmaceutical-Industry's-Next-Viagra http://www.visiongain.com/Report/216/Anti-addiction-Therapies-2006-2011-The-Pharmaceutical-Industry's-Next-Viagra pharma More money is spent advertising alcohol than any other product. For some, gambling and cigarettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease... info@visiongain.com (visiongain) Thu, 19 Oct 2006 00:00:00 GMT http://www.visiongain.com/Report/214/The-World-Allergy-Market-2006-2011-The-Rx-OTC-Rush http://www.visiongain.com/Report/214/The-World-Allergy-Market-2006-2011-The-Rx-OTC-Rush pharma The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide... info@visiongain.com (visiongain) Thu, 12 Oct 2006 00:00:00 GMT http://www.visiongain.com/Report/210/The-Global-Biotech-Report-2006-The-rise-of-the-Biotech-blockbusters http://www.visiongain.com/Report/210/The-Global-Biotech-Report-2006-The-rise-of-the-Biotech-blockbusters pharma It is here. The industry's leading Annual Biotech report has just been announced. Only 20 copies are available. So order your copy today... info@visiongain.com (visiongain) Fri, 15 Sep 2006 00:00:00 GMT http://www.visiongain.com/Report/209/Developing-Markets-for-Pharmaceuticals-2006-2011 http://www.visiongain.com/Report/209/Developing-Markets-for-Pharmaceuticals-2006-2011 pharma The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe at both regional and national level... info@visiongain.com (visiongain) Thu, 14 Sep 2006 00:00:00 GMT http://www.visiongain.com/Report/207/The-World-Asthma-and-COPD-Treatment-Market-2006-2011-A-Changing-Market-with-Increasing-Potential http://www.visiongain.com/Report/207/The-World-Asthma-and-COPD-Treatment-Market-2006-2011-A-Changing-Market-with-Increasing-Potential pharma The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort... info@visiongain.com (visiongain) Thu, 24 Aug 2006 00:00:00 GMT http://www.visiongain.com/Report/205/The-World-Contract-Research-and-Manufacturing-Market-2006-2011-(Trends-in-Outsourcing) http://www.visiongain.com/Report/205/The-World-Contract-Research-and-Manufacturing-Market-2006-2011-(Trends-in-Outsourcing) pharma The Contract Pharma market in 2005 was worth an estimated $57bn. Attitudes within the pharmaceutical industry are slowly changing and the use of strategic outsourcing is becoming an accepted practice... info@visiongain.com (visiongain) Thu, 03 Aug 2006 00:00:00 GMT http://www.visiongain.com/Report/204/ePharma-The-Online-Pharmaceutical-Industry-2006-2011 http://www.visiongain.com/Report/204/ePharma-The-Online-Pharmaceutical-Industry-2006-2011 pharma The purpose of this visiongain report is to examine the commercial prospects of online technologies in the pharmaceutical sector. In particular, this report examines the fast-growing fields of pharmaceutical eMarketing, eDetailing, ePrescribing and online drug sales... info@visiongain.com (visiongain) Fri, 28 Jul 2006 00:00:00 GMT http://www.visiongain.com/Report/199/Pharmacovigilance-Risk-Management-in-Practice http://www.visiongain.com/Report/199/Pharmacovigilance-Risk-Management-in-Practice pharma At present ADRs are the sixth largest cause of death in the US. Drug safety is a huge issue facing the industry today and the risk is high with the possible loss of a key revenue producing drug coupled with potentially damaging litigation... info@visiongain.com (visiongain) Mon, 17 Jul 2006 00:00:00 GMT http://www.visiongain.com/Report/198/Nanomedicine-2006-2011 http://www.visiongain.com/Report/198/Nanomedicine-2006-2011 pharma The purpose of this visiongain report is to examine the commercial prospects of nanotechnology in medicine - the fast-developing and increasingly lucrative field of nanomedicine... info@visiongain.com (visiongain) Thu, 29 Jun 2006 00:00:00 GMT http://www.visiongain.com/Report/194/Biogenerics-2006-Challenges-ahead-for-an-emerging-market http://www.visiongain.com/Report/194/Biogenerics-2006-Challenges-ahead-for-an-emerging-market pharma The world biogenerics market is about to develop on a very large scale. The approval of generic growth hormones in the US and Europe has finally occurred and this has created a new source of revenue for generic companies... info@visiongain.com (visiongain) Wed, 14 Jun 2006 00:00:00 GMT http://www.visiongain.com/Report/193/Indian-Pharmaceutical-Market-2006-2011 http://www.visiongain.com/Report/193/Indian-Pharmaceutical-Market-2006-2011 pharma The Indian pharmaceutical market is the 15th largest individual market by sales, but the 4th by volume of product. With domestic drug sales of almost $5 billion, Indian companies have also developed a considerable service industry for the global pharmaceutical market... info@visiongain.com (visiongain) Mon, 12 Jun 2006 00:00:00 GMT http://www.visiongain.com/Report/187/Product-Lifecycle-Management-2006 http://www.visiongain.com/Report/187/Product-Lifecycle-Management-2006 pharma The global pharmaceutical market with sales of approximately $550 billion is about to enter a pivotal period in its history. The industry has been used to double digit growth rates but growth has now dropped to below 10% for the first time... info@visiongain.com (visiongain) Thu, 18 May 2006 00:00:00 GMT http://www.visiongain.com/Report/188/The-World-Generics-Market-2006-2011 http://www.visiongain.com/Report/188/The-World-Generics-Market-2006-2011 pharma In sharp contrast to the branded pharmaceutical market, which has stalled in recent year, the generics market is enjoying a period of unprecedented success. In 2005 the world generics market was worth $45bn, a growth of 14% on the previous year... info@visiongain.com (visiongain) Thu, 18 May 2006 00:00:00 GMT http://www.visiongain.com/Report/180/The-World-Diabetes-Market-2005-2011 http://www.visiongain.com/Report/180/The-World-Diabetes-Market-2005-2011 pharma Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death... info@visiongain.com (visiongain) Mon, 27 Mar 2006 00:00:00 GMT http://www.visiongain.com/Report/175/The-Clinical-Trials-Market-2006 http://www.visiongain.com/Report/175/The-Clinical-Trials-Market-2006 pharma Will the current trend to outsource clinical trials to Asia be successful? How will the emerging discipline of pharmacogenomics affect drug development in the future? What kind of restrictions will authorities such as the FDA and the EMEA impose in the future? Read visiongain's brand new report... info@visiongain.com (visiongain) Fri, 10 Feb 2006 00:00:00 GMT http://www.visiongain.com/Report/173/The-World-Gastrointestinal-Disorders-Market-2006-2011 http://www.visiongain.com/Report/173/The-World-Gastrointestinal-Disorders-Market-2006-2011 pharma The purpose of this visiongain report is to examine the prospects of the world gastrointestinal market. The gastrointestinal (GI) disorders market is one of the largest and most important in the pharmaceutical industry, generating revenues of over $16 billion in 2004. info@visiongain.com (visiongain) Thu, 26 Jan 2006 00:00:00 GMT http://www.visiongain.com/Report/171/Japanese-Pharmaceutical-Market-2006-2011 http://www.visiongain.com/Report/171/Japanese-Pharmaceutical-Market-2006-2011 pharma The Japanese pharmaceutical market is the second largest individual market and with sales of $60 billion constitutes approximately 11% of the world market. However, it is a market that frustrates the major pharmaceutical companies as it is growing at a significantly lower rate of growth... info@visiongain.com (visiongain) Tue, 24 Jan 2006 00:00:00 GMT http://www.visiongain.com/Report/167/The-World-Market-for-Antidepressants-2006 http://www.visiongain.com/Report/167/The-World-Market-for-Antidepressants-2006 pharma In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010. info@visiongain.com (visiongain) Fri, 09 Dec 2005 00:00:00 GMT http://www.visiongain.com/Report/162/The-World's-Top-Ten-Generic-Companies http://www.visiongain.com/Report/162/The-World's-Top-Ten-Generic-Companies pharma Generic companies and the drugs they produce are now an important part of the major pharmaceutical markets. The growth rate in the industry is increasing, nine of the top ten fastest growing pharmaceutical companies are generic and the demand for cheaper drugs is increasing. info@visiongain.com (visiongain) Wed, 16 Nov 2005 00:00:00 GMT http://www.visiongain.com/Report/156/The-World-Hypertension-Market-2005-2010 http://www.visiongain.com/Report/156/The-World-Hypertension-Market-2005-2010 pharma The world hypertension market generated over $25 billion in 2004, with steady growth from the previous year. In this report, visiongain forecasts that revenues in the world hypertension market will grow to nearly $30 billion per year by 2010... info@visiongain.com (visiongain) Thu, 03 Nov 2005 00:00:00 GMT http://www.visiongain.com/Report/155/Pfizer-Current-Difficulties-and-Future-Challenges-2005-2010 http://www.visiongain.com/Report/155/Pfizer-Current-Difficulties-and-Future-Challenges-2005-2010 pharma Pfizer has just issued a warning on how deep the pharmaceutical industry's problems have gone. The company has cut its profit expectations for this year. It has also withdrawn its previously optimistic forecasts for the next two years. With sales of over $52 billion and 17 per cent growth in 2003/04, it leads the pharmaceutical market and has influenced the way the market is shaped. What Pfizer does, you need to take notice of. info@visiongain.com (visiongain) Thu, 27 Oct 2005 00:00:00 GMT http://www.visiongain.com/Report/148/The-World-Sleep-Disorders-Market-2005-2010 http://www.visiongain.com/Report/148/The-World-Sleep-Disorders-Market-2005-2010 pharma The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first real competition for Ambien arrived on the market in the form of Estorra from Sepracor. info@visiongain.com (visiongain) Wed, 14 Sep 2005 00:00:00 GMT http://www.visiongain.com/Report/150/The-World-Schizophrenia-Market-2005-2010 http://www.visiongain.com/Report/150/The-World-Schizophrenia-Market-2005-2010 pharma The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market? Did you benefit from the strong growth in 2003 and 2004? With almost all the leading drugs also approved for treating aspects of bipolar disorder, the opportunities for drugs in this market are increasing rapidly... info@visiongain.com (visiongain) Thu, 25 Aug 2005 00:00:00 GMT http://www.visiongain.com/Report/1/Pricing-and-Reimbursement-2005-2006-Evaluating-Key-Strategic-Issues http://www.visiongain.com/Report/1/Pricing-and-Reimbursement-2005-2006-Evaluating-Key-Strategic-Issues pharma One of the two major issues for a drug company, besides gaining market authorisation, is persuading the country in question to reimburse them, that is pay for the drug that the company is attempting to market... info@visiongain.com (visiongain) Wed, 10 Aug 2005 00:00:00 GMT http://www.visiongain.com/Report/2/The-World-Biotech-Market-2005 http://www.visiongain.com/Report/2/The-World-Biotech-Market-2005 pharma The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents... info@visiongain.com (visiongain) Fri, 17 Jun 2005 00:00:00 GMT http://www.visiongain.com/Report/3/Urinary-Tract-Agents-Annual-Report-2005 http://www.visiongain.com/Report/3/Urinary-Tract-Agents-Annual-Report-2005 pharma This report focuses on marketed and in-development products with primary indications for urinary tract disorders. It represents a key tool for companies wishing to enter into or expand in the urinary tract agent market... info@visiongain.com (visiongain) Tue, 19 Apr 2005 00:00:00 GMT http://www.visiongain.com/Report/4/The-Global-Endocrine-Pharmaceutical-Market-2005 http://www.visiongain.com/Report/4/The-Global-Endocrine-Pharmaceutical-Market-2005 pharma Today, the global endocrine pharmaceutical market is a highly lucrative multi-billion dollar business, but, can you confidently answer the following?... info@visiongain.com (visiongain) Fri, 18 Mar 2005 00:00:00 GMT http://www.visiongain.com/Report/7/Therapeutic-Proteins http://www.visiongain.com/Report/7/Therapeutic-Proteins pharma Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs... info@visiongain.com (visiongain) Mon, 21 Feb 2005 00:00:00 GMT http://www.visiongain.com/Report/248/Cannabinoids-A-potential-blockbuster http://www.visiongain.com/Report/248/Cannabinoids-A-potential-blockbuster pharma Visiongain values todays limited cannabinoid market at just $110.5m in 2005. Having grew 6.3% from 2004's revenues of $104 m, growth of the market will continue over the forecast period 2002-2010. Two forecast projections are made by visiongain in this report: if no comers arrive and the potential value following launch of the key future products. info@visiongain.com (visiongain) Mon, 21 Feb 2005 00:00:00 GMT http://www.visiongain.com/Report/152/World-Neurodegeneratives-Disease-Markets-2005-2009 http://www.visiongain.com/Report/152/World-Neurodegeneratives-Disease-Markets-2005-2009 pharma Is the neurodegeneratives disease market growing? Are current drug therapies valuable? What are the current unmet needs in this market? What is the future of this market? info@visiongain.com (visiongain) Fri, 04 Feb 2005 00:00:00 GMT http://www.visiongain.com/Report/27/The-World-Pharmaceutical-Wholesale-and-Distribution-Industry-2005 http://www.visiongain.com/Report/27/The-World-Pharmaceutical-Wholesale-and-Distribution-Industry-2005 pharma The importance of the Wholesale & Distribution sector of the pharmaceutical industry is often overlooked, but with the EU alone boasting some 3,000 pharmaceutical manufacturers... info@visiongain.com (visiongain) Tue, 25 Jan 2005 00:00:00 GMT http://www.visiongain.com/Report/9/Pharmacoeconomics http://www.visiongain.com/Report/9/Pharmacoeconomics pharma Pharmacoeconomics is the branch of economics that applies cost-benefit, cost-effectiveness, cost-minimisation, and cost-utility analyses to compare the economics of different pharmaceutical products or to compare drug therapy to other treatments... info@visiongain.com (visiongain) Wed, 19 Jan 2005 00:00:00 GMT http://www.visiongain.com/Report/10/The-World-Market-for-In-Vitro-Diagnostics-2005 http://www.visiongain.com/Report/10/The-World-Market-for-In-Vitro-Diagnostics-2005 pharma According to in depth analysis by Dr Ray Scraggs, Senior Medical Writer with visiongain, the world market in 2005 for In Vitro Diagnostics will be in excess of $20bn... info@visiongain.com (visiongain) Wed, 19 Jan 2005 00:00:00 GMT http://www.visiongain.com/Report/51/The-Global-Veterinary-Pharmaceutical-Market http://www.visiongain.com/Report/51/The-Global-Veterinary-Pharmaceutical-Market pharma Although the pet population has increased marginally, the key driver for growth has been the willingness of pet owners to spend more on the health of their animals and the ability of veterinarians to meet that need. info@visiongain.com (visiongain) Sun, 16 Jan 2005 00:00:00 GMT http://www.visiongain.com/Report/5/Anticonvulsants-2005 http://www.visiongain.com/Report/5/Anticonvulsants-2005 pharma Anticonvulsant therapies encompass all drugs used primarily to prevent seizures or control their incidence or severity. These drugs are however versatile and can be used for a variety of other disorders, namely bipolar disorder, neuropathic pain and migraine prophylaxis... info@visiongain.com (visiongain) Thu, 13 Jan 2005 00:00:00 GMT http://www.visiongain.com/Report/241/Bone-Metabolism-Regulators-2004-2009-Market-forecasts-and-analysis http://www.visiongain.com/Report/241/Bone-Metabolism-Regulators-2004-2009-Market-forecasts-and-analysis pharma Affecting over 200 million people worldwide osteoporosis and other bone diseases are a significant market sector for the pharmaceutical industry. In 2003, the bone metabolism regulator (BMR) market was worth $7.2bn. Is your company part of this market? If not, how can you enter or expand into the BMR market? info@visiongain.com (visiongain) Wed, 15 Dec 2004 00:00:00 GMT http://www.visiongain.com/Report/11/The-Global-Ophthalmic-Pharmaceutical-Market-2004-2009 http://www.visiongain.com/Report/11/The-Global-Ophthalmic-Pharmaceutical-Market-2004-2009 pharma Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 13.0% to 2009... info@visiongain.com (visiongain) Wed, 08 Dec 2004 00:00:00 GMT http://www.visiongain.com/Report/12/Orphan-Drugs-Future-Directions-for-a-High-Growth-Market-2004-2009 http://www.visiongain.com/Report/12/Orphan-Drugs-Future-Directions-for-a-High-Growth-Market-2004-2009 pharma In 1983 there were just 10 orphan drugs available to treat rare diseases, but in the space of 20 years there are now 210 different drugs resulting in a market that is worth more than $27 billion today... info@visiongain.com (visiongain) Fri, 05 Nov 2004 00:00:00 GMT http://www.visiongain.com/Report/14/Blockbuster-Drugs-A-Current-Assessment-and-Outlook-for-Creating-Future-Blockbusters http://www.visiongain.com/Report/14/Blockbuster-Drugs-A-Current-Assessment-and-Outlook-for-Creating-Future-Blockbusters pharma A blockbuster drug is defined as a medicine that generates more than $1 billion (U.S.) in sales in a year. How many Blockbuster Drugs does your company produce? The blockbuster market in 2003 consisted of 67 drugs, which alone, generated over $136 billion... info@visiongain.com (visiongain) Thu, 04 Nov 2004 00:00:00 GMT http://www.visiongain.com/Report/201/AIDS-2004 http://www.visiongain.com/Report/201/AIDS-2004 pharma Today Aquired Immune Defiency Syndrome (AIDS) continues to devastate the world. By the end of 2003, the World Health Organisation estimated that a somewhat stagerring 37 million adults were living with HIV/AIDS worldwide... info@visiongain.com (visiongain) Wed, 03 Nov 2004 00:00:00 GMT http://www.visiongain.com/Report/15/The-Cardiovascular-Report-3rd-Annual-Edition http://www.visiongain.com/Report/15/The-Cardiovascular-Report-3rd-Annual-Edition pharma Cardiovascular has been the leading therapeutic category for over two decades and is set to continue its pace of expansion and dominance over the global drugs market... info@visiongain.com (visiongain) Wed, 20 Oct 2004 00:00:00 GMT http://www.visiongain.com/Report/13/Top-10-Biotech-Companies-2004-Innovators-and-Leaders-in-the-Market http://www.visiongain.com/Report/13/Top-10-Biotech-Companies-2004-Innovators-and-Leaders-in-the-Market pharma More than 325 million people worldwide have been helped by the more than 130 biotechnology drugs and vaccines approved by the US FDA... info@visiongain.com (visiongain) Thu, 16 Sep 2004 00:00:00 GMT http://www.visiongain.com/Report/16/Statins-and-the-AntiCholesterol-Market-2004-2009 http://www.visiongain.com/Report/16/Statins-and-the-AntiCholesterol-Market-2004-2009 pharma Will we all be on statins by the time we are 55? This is a huge market and your company should be part of it now... info@visiongain.com (visiongain) Fri, 03 Sep 2004 00:00:00 GMT http://www.visiongain.com/Report/31/Pharmacogenomics-A-Personalized-Approach-to-Medicine http://www.visiongain.com/Report/31/Pharmacogenomics-A-Personalized-Approach-to-Medicine pharma This visiongain report provides you with the most comprehensive guide to personalized medicines, numerous multicolored graphs and uniquely compiled tables containing industry facts and figures... info@visiongain.com (visiongain) Tue, 31 Aug 2004 00:00:00 GMT http://www.visiongain.com/Report/19/Modern-Drug-Discovery-Markets-2004-2009 http://www.visiongain.com/Report/19/Modern-Drug-Discovery-Markets-2004-2009 pharma With increasing lead times and cost of drug development your company needs to find new drugs, quicker and cheaper than before... info@visiongain.com (visiongain) Fri, 23 Jul 2004 00:00:00 GMT http://www.visiongain.com/Report/18/Collaborations-and-Licensing-in-Global-Pharmaceuticals-and-Biotech http://www.visiongain.com/Report/18/Collaborations-and-Licensing-in-Global-Pharmaceuticals-and-Biotech pharma Industry developments of the last 10 years have changed the shape of your industry. Discovering and bringing one new drug to market typically costs a pharmaceutical or biotechnology company nearly $900 million and takes an average of 10 to 12 years... info@visiongain.com (visiongain) Wed, 21 Jul 2004 00:00:00 GMT http://www.visiongain.com/Report/20/The-Pain-Report-2004 http://www.visiongain.com/Report/20/The-Pain-Report-2004 pharma The global pain management market was $21.6 billion in 2000 and it is expected to increase at a compounded annual growth rate of 4.7 percent to reach $29.7 billion in 2007... info@visiongain.com (visiongain) Tue, 13 Jul 2004 00:00:00 GMT http://www.visiongain.com/Report/21/The-World-Erectile-Dysfunction-Markets-2004-2009 http://www.visiongain.com/Report/21/The-World-Erectile-Dysfunction-Markets-2004-2009 pharma According to indepth analysis from Dr Ray Scraggs, of visiongain's management report writing team, in 2003 revenues for the market of erectile dysfunction drugs was $2.12bn and is set to more than triple by 2009... info@visiongain.com (visiongain) Tue, 13 Jul 2004 00:00:00 GMT http://www.visiongain.com/Report/24/Angiogenesis-Inhibitors-and-Stimulators-The-Emergence-of-a-New-Market http://www.visiongain.com/Report/24/Angiogenesis-Inhibitors-and-Stimulators-The-Emergence-of-a-New-Market pharma The first angiogenesis inhibitor has been approved. Genentech's Avastin will set the pace for the uptake of these novel drugs that will prove to have a major impact on the cancer and autoimmune markets... info@visiongain.com (visiongain) Wed, 09 Jun 2004 00:00:00 GMT http://www.visiongain.com/Report/25/The-World-Market-for-Anti-Fungal-Therapies http://www.visiongain.com/Report/25/The-World-Market-for-Anti-Fungal-Therapies pharma According to indepth analysis from Dr Ray Scraggs, Senior Pharmaceutical Industry Analyst with visiongain the total value of the world market for antifungal medication... info@visiongain.com (visiongain) Tue, 08 Jun 2004 00:00:00 GMT http://www.visiongain.com/Report/26/Antisense-Therapies-2004-Commercialization-and-Research-Trends http://www.visiongain.com/Report/26/Antisense-Therapies-2004-Commercialization-and-Research-Trends pharma The market for antisense therapeutics is set to take off in 2004 with approval nearing for Genasense, a novel antisense drug that will treat melanoma, a disease for which there is great unmet need still... info@visiongain.com (visiongain) Tue, 08 Jun 2004 00:00:00 GMT http://www.visiongain.com/Report/56/Cancer-Therapies-2004-New-Market-Dynamics-and-Products http://www.visiongain.com/Report/56/Cancer-Therapies-2004-New-Market-Dynamics-and-Products pharma There is a one-in-three chance of being diagnosed with some type of cancer. The amount of resources that have been organized to effectively meet this threat are enormous... info@visiongain.com (visiongain) Wed, 05 May 2004 00:00:00 GMT http://www.visiongain.com/Report/54/Controlled-Release-The-Future-of-Drug-Delivery http://www.visiongain.com/Report/54/Controlled-Release-The-Future-of-Drug-Delivery pharma Drug delivery is growing rapidly. Advanced drug delivery accounts for 6 per cent of the global pharmaceutical market and this figure is estimated to grow to 20 per cent by 2005... info@visiongain.com (visiongain) Wed, 28 Apr 2004 00:00:00 GMT http://www.visiongain.com/Report/58/Biotech-Israel http://www.visiongain.com/Report/58/Biotech-Israel pharma Despite the regions tumultuous history, Israel has succeeded in developing a technologically advanced economy. Throughout the 1990s technologies markets evolved... info@visiongain.com (visiongain) Wed, 28 Apr 2004 00:00:00 GMT http://www.visiongain.com/Report/17/Pharmaceutical-Packaging-and-Labeling-New-Techniques-and-Market-Trends http://www.visiongain.com/Report/17/Pharmaceutical-Packaging-and-Labeling-New-Techniques-and-Market-Trends pharma The role of packaging and labeling in the pharmaceutical industry has grown substantially over the past decade. In 2002, the overall demand for pharmaceutical packaging reached $15 billion... info@visiongain.com (visiongain) Wed, 28 Apr 2004 00:00:00 GMT http://www.visiongain.com/Report/59/The-World-Antibiotics-Market-2002-2009 http://www.visiongain.com/Report/59/The-World-Antibiotics-Market-2002-2009 pharma The total world market for antibiotics in 2002 was over $26bn. In 2002 the world market for miscellaneous antibiotics generated revenues of $2.9bn... info@visiongain.com (visiongain) Tue, 16 Mar 2004 00:00:00 GMT http://www.visiongain.com/Report/48/Venture-Capital-Investment-in-Biotech http://www.visiongain.com/Report/48/Venture-Capital-Investment-in-Biotech pharma The venture capital market is on the increase. Expansion companies received around $13.3 billion (equivalent to 63% of total market investments... info@visiongain.com (visiongain) Tue, 16 Mar 2004 00:00:00 GMT http://www.visiongain.com/Report/50/The-Therapeutic-and-Prophylactic-Vaccine-Market http://www.visiongain.com/Report/50/The-Therapeutic-and-Prophylactic-Vaccine-Market pharma The world vaccine market, once characterized by slow growth, has seen increased sales as a result of new paediatric vaccines... info@visiongain.com (visiongain) Wed, 10 Mar 2004 00:00:00 GMT http://www.visiongain.com/Report/57/The-Pharmaceutical-Control-of-Blood-Diseases http://www.visiongain.com/Report/57/The-Pharmaceutical-Control-of-Blood-Diseases pharma The total value in 2002 of the blood diseases market was worth $20bn. Shouldn't you and your company have a larger share of this market?... info@visiongain.com (visiongain) Tue, 09 Mar 2004 00:00:00 GMT http://www.visiongain.com/Report/60/Achieving-Success-in-the-Indian-Pharmaceutical-Sector http://www.visiongain.com/Report/60/Achieving-Success-in-the-Indian-Pharmaceutical-Sector pharma The Indian pharmaceutical industry is highly fragmented. It has grown rapidly due to a lenient patent regime and low cost manufacturing structure... info@visiongain.com (visiongain) Tue, 27 Jan 2004 00:00:00 GMT http://www.visiongain.com/Report/159/Anti-Migraine-Market-Report http://www.visiongain.com/Report/159/Anti-Migraine-Market-Report pharma What is the projected market growth of anti-migraine drugs next year? What is the projected sales of abortive and prophylactic migraine therapies in the 7 major pharmaceutical markets? info@visiongain.com (visiongain) Tue, 27 Jan 2004 00:00:00 GMT http://www.visiongain.com/Report/47/Women's-Reproductive-Health-2004 http://www.visiongain.com/Report/47/Women's-Reproductive-Health-2004 pharma The combined value of the women's reproductive health pharmaceutical market is currently over $20 billion. A positive growth rate of 8 per cent is expected per annum for the next five years... info@visiongain.com (visiongain) Fri, 23 Jan 2004 00:00:00 GMT http://www.visiongain.com/Report/52/The-Global-Antivirals-Market-2004-2008 http://www.visiongain.com/Report/52/The-Global-Antivirals-Market-2004-2008 pharma This visiongain report: 'The Global Antivirals Market, 2004-2008' will provide you with the most up to date comprehensive guide to the Antivirals Industry... info@visiongain.com (visiongain) Wed, 14 Jan 2004 00:00:00 GMT http://www.visiongain.com/Report/53/Is-this-the-End-of-HRT http://www.visiongain.com/Report/53/Is-this-the-End-of-HRT pharma The market for Hormone Replacement Therapy (HRT) is rich and lucrative. In 2001 the market was worth over $3.3 billion and at that time still growing... info@visiongain.com (visiongain) Tue, 16 Dec 2003 00:00:00 GMT http://www.visiongain.com/Report/55/Contract-Research-and-Manufacture-in-the-Global-Pharmaceutical-Industry-2004 http://www.visiongain.com/Report/55/Contract-Research-and-Manufacture-in-the-Global-Pharmaceutical-Industry-2004 pharma The industry for the outsourcing of activities associated with the development and manufacture of pharmaceutical products has been an arena of considerable change in recent years... info@visiongain.com (visiongain) Wed, 05 Nov 2003 00:00:00 GMT http://www.visiongain.com/Report/45/Antidepressant-Market-Forecasts-2003-2008 http://www.visiongain.com/Report/45/Antidepressant-Market-Forecasts-2003-2008 pharma In 2002, the market for antidepressants accounted for around $17 billion of the $49 billion market for CNS therapies ... info@visiongain.com (visiongain) Tue, 04 Nov 2003 00:00:00 GMT http://www.visiongain.com/Report/22/Tissue-Engineering-and-Stem-Cell-Technology-Report-2003-2013 http://www.visiongain.com/Report/22/Tissue-Engineering-and-Stem-Cell-Technology-Report-2003-2013 pharma There may be no stem cell products on the market at present but the potential of this technology is so huge that revenues may be in excess of $10 billion by 2013... info@visiongain.com (visiongain) Thu, 30 Oct 2003 00:00:00 GMT http://www.visiongain.com/Report/32/Combating-Pharmaceutical-Fraud-Counterfeiting-Report-2004 http://www.visiongain.com/Report/32/Combating-Pharmaceutical-Fraud-Counterfeiting-Report-2004 pharma The counterfeiting and selling of Western pharmaceuticals is responsible for killing people... info@visiongain.com (visiongain) Thu, 02 Oct 2003 00:00:00 GMT http://www.visiongain.com/Report/37/Global-Respiratory-Drugs-2003-2006 http://www.visiongain.com/Report/37/Global-Respiratory-Drugs-2003-2006 pharma - Respiratory illness effects more than 1 billion people. - Asthma is on the increase - Respiratory drugs generated a total revenue of more than $25 billion... info@visiongain.com (visiongain) Thu, 18 Sep 2003 00:00:00 GMT http://www.visiongain.com/Report/49/The-World-Skin-Diseases-Market-2004 http://www.visiongain.com/Report/49/The-World-Skin-Diseases-Market-2004 pharma This visiongain report provides you with the most comprehensive guide to the Skin Diseases Market with a thorough detailed revenues analysis of all the important drugs involved from 2001 to 2008... info@visiongain.com (visiongain) Thu, 21 Aug 2003 00:00:00 GMT http://www.visiongain.com/Report/44/The-Global-Anti-Obesity-Pharmaceutical-Market-Report-2003-2008 http://www.visiongain.com/Report/44/The-Global-Anti-Obesity-Pharmaceutical-Market-Report-2003-2008 pharma - The global market for obesity treatments is expected to more than double over the next 10 years. - What will the global obesity prescription market be worth in 2010?... info@visiongain.com (visiongain) Mon, 18 Aug 2003 00:00:00 GMT http://www.visiongain.com/Report/34/Monoclonal-Antibodies-Report-2003-Meeting-Clinical-and-Financial-Expectations http://www.visiongain.com/Report/34/Monoclonal-Antibodies-Report-2003-Meeting-Clinical-and-Financial-Expectations pharma The recent success of a number of new monoclonal antibody therapies suggests a resurgence in the biotechnology industry that is set to be realized in 2003 and the coming years... info@visiongain.com (visiongain) Fri, 01 Aug 2003 00:00:00 GMT http://www.visiongain.com/Report/46/The-World-Wound-Care-Markets-2001-2008 http://www.visiongain.com/Report/46/The-World-Wound-Care-Markets-2001-2008 pharma According to indepth analysis by visiongain, the value in 2002 of the world market for wound care products was nearly $6bn. But what will it be in 2008?... info@visiongain.com (visiongain) Wed, 23 Jul 2003 00:00:00 GMT http://www.visiongain.com/Report/35/Mail-Order-Pharmacy-Market-2003-2008 http://www.visiongain.com/Report/35/Mail-Order-Pharmacy-Market-2003-2008 pharma - The prescription mail order market is currently worth US$19.8 billion but what size will it be by the end of 2008? - Will on-line pharmacies show the greatest growth and increased revenues?... info@visiongain.com (visiongain) Thu, 10 Jul 2003 00:00:00 GMT http://www.visiongain.com/Report/6/Parallel-Trade-In-Global-Pharma-2003 http://www.visiongain.com/Report/6/Parallel-Trade-In-Global-Pharma-2003 pharma By its simplest definition, parallel trade is borne out of pricing differentials between high and low cost regions - but the whole story is far from a simple process made possible by a single loophole... info@visiongain.com (visiongain) Fri, 27 Jun 2003 00:00:00 GMT http://www.visiongain.com/Report/161/Chinese-Pharmaceutical-Markets-The-selling-of-traditional-western-drugs-to-China http://www.visiongain.com/Report/161/Chinese-Pharmaceutical-Markets-The-selling-of-traditional-western-drugs-to-China pharma In 2001, China was listed seventh in world for pharmaceutical sales (bulk pharmaceuticals / APIs and TCMs not included) but a huge expansion in sales may see the Chinese market becoming second to the USA by 2020, with revenues predicted to be in excess of $60 billion... info@visiongain.com (visiongain) Wed, 11 Jun 2003 00:00:00 GMT http://www.visiongain.com/Report/28/US-Canada-Reimportation-Report http://www.visiongain.com/Report/28/US-Canada-Reimportation-Report pharma Glaxo and AstraZeneca are limiting supplies of drugs to Canada - who will be next?... info@visiongain.com (visiongain) Fri, 06 Jun 2003 00:00:00 GMT http://www.visiongain.com/Report/40/Drug-Delivery-2003-New-Technologies-in-the-Global-Market http://www.visiongain.com/Report/40/Drug-Delivery-2003-New-Technologies-in-the-Global-Market pharma In 2002, revenues of pharma products which utilize advanced drug delivery technology reached $38 billion... info@visiongain.com (visiongain) Fri, 16 May 2003 00:00:00 GMT http://www.visiongain.com/Report/29/The-SARS-Report-Worldwide-Pharma-Analysis-May-2003 http://www.visiongain.com/Report/29/The-SARS-Report-Worldwide-Pharma-Analysis-May-2003 pharma -- A profoundly threatening new epidemic -- easily transmissible -- capable of killing 4 percent of the people who contract it... info@visiongain.com (visiongain) Tue, 29 Apr 2003 00:00:00 GMT http://www.visiongain.com/Report/147/Wholesale-Distribution-Examination-of-the-UK-US-and-European-regional-markets-for-prescription-pharmaceuticals http://www.visiongain.com/Report/147/Wholesale-Distribution-Examination-of-the-UK-US-and-European-regional-markets-for-prescription-pharmaceuticals pharma The importance of the Wholesale & Distribution sector of the pharmaceutical industry is often overlooked, but with the EU alone boasting some 3,000 pharmaceutical manufacturers producing some 50,000 products for 130,000 retail outlets, the supporting network provided by the wholesale distributor is essential to the healthcare industry. info@visiongain.com (visiongain) Wed, 16 Apr 2003 00:00:00 GMT http://www.visiongain.com/Report/33/Neurodegenerative-Diseases-World-Markets-2002-2007 http://www.visiongain.com/Report/33/Neurodegenerative-Diseases-World-Markets-2002-2007 pharma The ageing of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to... info@visiongain.com (visiongain) Fri, 04 Apr 2003 00:00:00 GMT http://www.visiongain.com/Report/42/Diabetes-Report-2003 http://www.visiongain.com/Report/42/Diabetes-Report-2003 pharma Over 12 months through September 2000, the global retail sales of diabetes drugs were US$8.1 billion... info@visiongain.com (visiongain) Tue, 01 Apr 2003 00:00:00 GMT http://www.visiongain.com/Report/39/Endocrine-Disease-Treatments-2002-2007-2nd-Annual-Edition http://www.visiongain.com/Report/39/Endocrine-Disease-Treatments-2002-2007-2nd-Annual-Edition pharma " In 2001 the pharmaceutical market for the treatment of endocrine diseases was worth $30.1 billion, with a growth rate of 4.9% from the previous year "... info@visiongain.com (visiongain) Fri, 14 Feb 2003 00:00:00 GMT http://www.visiongain.com/Report/41/Direct-to-consumer-advertising-prescription-drug-promotion http://www.visiongain.com/Report/41/Direct-to-consumer-advertising-prescription-drug-promotion pharma Spending on the promotion of prescription drugs have increased significantly in recent years, closing at $12.5 billion in 2001... info@visiongain.com (visiongain) Sun, 01 Dec 2002 00:00:00 GMT http://www.visiongain.com/Report/64/Anti-Infectives-2002 http://www.visiongain.com/Report/64/Anti-Infectives-2002 pharma * The leading Anti-Infectives report of 2002- available today * Over 350 pages FULL of graphs, charts & analysis - you cannot afford to ignore this report... info@visiongain.com (visiongain) Sun, 01 Dec 2002 00:00:00 GMT http://www.visiongain.com/Report/36/Heart-Cardiovascular-Disease-2002 http://www.visiongain.com/Report/36/Heart-Cardiovascular-Disease-2002 pharma The pharmaceutical market is fiercely competitive, yet cardiovascular therapies have maintained the lead position for over two decades... info@visiongain.com (visiongain) Fri, 01 Nov 2002 00:00:00 GMT http://www.visiongain.com/Report/63/CNS-Report-2002 http://www.visiongain.com/Report/63/CNS-Report-2002 pharma In 2001 CNS therapies held a market share worth in excess on $40 billion - the strongest growth of any therapeutic class with a staggering 17 per cent... info@visiongain.com (visiongain) Tue, 01 Oct 2002 00:00:00 GMT http://www.visiongain.com/Report/38/Future-Pain-Drugs-2002 http://www.visiongain.com/Report/38/Future-Pain-Drugs-2002 pharma Though strong competition from generics has limited revenues in the pain management market, changing attitudes towards pain treatment are revitalizing... info@visiongain.com (visiongain) Tue, 27 Aug 2002 00:00:00 GMT http://www.visiongain.com/Report/43/Blockbuster-Drugs-Create-Develop-and-Market-a-Billion-Dollar-Drug http://www.visiongain.com/Report/43/Blockbuster-Drugs-Create-Develop-and-Market-a-Billion-Dollar-Drug pharma In 1992 only 4 Blockbuster drugs existed. The number jumped in 1998 to 29 and again in 2000 to 55. What is it now? This report will tell you... info@visiongain.com (visiongain) Mon, 01 Apr 2002 00:00:00 GMT http://www.visiongain.com/Report/160/Cancer-2002 http://www.visiongain.com/Report/160/Cancer-2002 pharma There are currently more new drugs in development for the treatment of cancer than there are cancer indications. Many anti-cancer drugs and therapies are as well known for the associated side effects as their therapeutic benefit... info@visiongain.com (visiongain) Tue, 15 Jan 2002 00:00:00 GMT